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Abstract 
 
Anti-lipid antibody in M. tuberculosis infection-- basis for a new biomarker-based 
test to monitor treatment response 
 
By 
 
Amador Darnley Goodridge Johnson 
 
Doctor of Philosophy in Infectious Diseases and Immunity 
 
University of California, Berkeley 
 
Professor: Lee W. Riley, Chair 
 
 Tuberculosis (TB) faces difficult challenges for its treatment and control.  Both the 
diagnosis of TB and Mycobacterium tuberculosis (M. tuberculosis) drug susceptibility 
testing take weeks and clinicians often do not know if the patient is taking an appropriate 
set of drugs until complications or even death occur.  Consequently, early determination 
of a successful drug therapy response in individuals infected with M. tuberculosis is 
urgently needed.  Since the M. tuberculosis cell wall is comprised of a diverse repertoire 
of lipids, we examined the possible role of these lipids as antigens for serologic response 
during M. tuberculosis infection.  This dissertation is focused on the examination of lipid-
antibody response as a potential biomarker used to monitor treatment response in M. 
tuberculosis infected hosts.  Briefly, Chapter 1 describes the current pitfalls of monitoring 
tuberculosis treatment with current methods, including acid-fast bacilli (AFB) smear and 
culture conversion.  Chapter 1 also covers the definition of biomarkers and the rationale 
to use M. tuberculosis cell wall lipids to develop an anti-lipid-antibody based test.  
Evidence from a similar biomarker-based test for syphilis is presented.  The chapter also 
discusses the biological basis which guided the lipid-antibody biomarker search and 
discovery.   
 Chapter 2 describes the use of a serum bank from patients with pulmonary TB 
provided by the World Health Organization–Tropical Diseases Research consortium 
(WHO-TDR) to identify M. tuberculosis lipid candidates as targets of antibody response.  
These samples were used to look for an antibody response to multiple mycobacterial 
lipids resolved by thin-layer chromatography immunoblot (TLC-I).  This approach 
allowed us to identify M. tuberculosis cardiolipin by mass spectrometry and we 
determined that the IgM antibody response to cardiolipin can be used as a biomarker of 
infection.   
 In Chapter 3, we investigate the biological evidence behind the production of anti-
phospholipid IgM antibody during TB infection and anti-TB treatment.  For this purpose, 
we used the Cornell mouse model of infection to monitor the change in IgM antibody 
response against four phospholipids including cardiolipin (CL), phosphatidyl choline 
(PTC), phosphatidyl ethanolamine (PE) and phosphatidyl inositol (PI) over the course of 
M. tuberculosis infection and treatment.  We separated BALB/c mice into three groups 
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including acute infection (AI), chronic infection (CI), and healthy control (HC).  Both AI 
and CI groups were infected via the aerosol route with M. tuberculosis strain H37Rv at 
day 0.  The AI group was treated from 4 to 12 weeks post-infection, while the CI group 
was treated from 20 to 28 weeks post-infection.  We also measured the levels of pro-
inflammatory cytokines, IL-5 and MCP-1.  We observed that in treated AI mice, anti-
phospholipid IgM antibody levels decreased compared to those of healthy mice at all 
time points. Anti-PTC IgM antibodies remained significantly higher in CI mice than in 
AI mice at all time points post-infection.  The anti-PTC IgM antibody levels in CI mice 
decreased to levels similar to those of AI and HC mice at 32 weeks post-infection.  The 
anti-phospholipid IgM antibody levels correlated with the bacterial load in the lungs, with 
treated mice showing fewer M. tuberculosis colony-forming units (CFU) after eight 
weeks of treatment.  Furthermore, IL-5 was mainly produced by the site of infection in 
the lung and decreased with anti-tuberculosis treatment within the CI mice group. 
 Finally, in Chapter 4, we examine the use of anti-phospholipid IgM antibody changes 
as a biomarker for treatment response in patients with smear positive pulmonary TB.  
Serum samples were obtained from pulmonary TB patients at the start and end of the 
intensive phase of treatment (40 doses of anti-TB combination therapy) enrolled from 
Kampala, Uganda in a CDC-TB Trials Consortium randomized clinical trial.  The 
samples were screened for IgM antibody levels against five commercially available 
phospholipids by an in-house ELISA assay.  The lipid antigens included CL, PI, PE, 
PTC, and sphingolipid (SL).  IgM antibody levels to CL, PE, PI, PTC and SL 
significantly decreased following anti-TB drug treatment in patients without lung cavities 
on their baseline chest radiograph.  In contrast, patients with cavitary TB showed an 
overall increase in the anti-phospholipid IgM antibody response following anti-TB drug 
treatment, notably with a significant increase in anti-PE antibody levels.  Thus, anti-lipid 
IgM response appears to be a useful biomarker for treatment response, especially in those 
with non-cavitary disease. 
 Chapter 5 summarizes the conclusions in support of using the anti-phospholipid IgM 
antibody response as a useful biomarker for monitoring TB treatment response.  This 
novel biomarker test would greatly facilitate TB management in resource-poor settings.  
The development of a point of care (POC) test based on anti-phospholipid IgM antibody 
will be an affordable and highly sensitive alternative to microscopy or culture testing for 
monitoring treatment response in individuals with TB.  Chapter 5 also gives examples of 
three platforms that might be used for the development of such a POC test.  However, we 
note that it is necessary to explore the specificity of this assay further by testing patients 
with HIV infection, latent TB infection, and non-TB pulmonary diseases.   
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Chapter 1 
 
Introduction to tuberculosis biomarker-based tests 
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I. Definition: Tuberculosis (TB) is an infectious disease caused by members of the 
Mycobacterium tuberculosis complex, which includes Mycobacterium tuberculosis (M. 
tuberculosis), M. caprae, M. microti, M. pinnipedii, M. africanum, and M. canettii (the latter 
two are responsible for a small number of cases in Africa). These three species mainly affect 
humans while M. bovis, which is also part of the M. tuberculosis complex group, is involved 
primarily with cattle infection. Mycobacteria other than tuberculosis (MOTT) can cause 
pulmonary TB in humans.  These are also known as non-tuberculous mycobacteria (NTM) 
and affect mainly immunocompromised patients as well as the elderly (Taiwo and Glassroth 
2010).   
Initial exposure to TB occurs by inhalation of aerosolized M .tuberculosis bacilli and 
inhalation is the main route of transmission of pulmonary TB.  Initial infection usually goes 
unnoticed and may be detected by the tuberculin skin test (TST) within 2 to 10 weeks after 
infection.  Early lung lesions commonly heal, leaving no residual changes except for 
occasional pulmonary lymph node calcification.  However, about 10% of those initially 
infected will eventually develop active disease, half of them during the first 2 years following 
the infection.  The remaining 90% of infected individuals will harbor the bacteria in a latent 
stage and never develop active disease (Heymann 2004).   
Additionally, recurrence of TB can result from a relapse of disease from the same strain 
that caused the original episode or from infection by another strain, also called “exogenous re-
infection” (Cole, Davis et al. 2005).  TB recurrence is defined as a second episode of disease 
after a patient has completed treatment and has been deemed cured of tuberculosis (WHO 
2008).   
 
II. Epidemiology of Tuberculosis: TB occurrence is worldwide.  The annual incidence varies 
by world region with the highest burden of the disease found in African and Asian countries.  
According to the World Health Organization (WHO), nearly 2 billion people—one-third of 
the world's population—have been infected with the M. tuberculosis bacilli.  Annually, 8 
million people become ill with TB, and nearly 2 million people die from the disease 
worldwide. In 2004, an estimated 14.6 million people had active disease with 9 million new 
cases (WHO 2007).  In the United States, the incidence is 4.4 per 100,000 inhabitants per 
year.  In the state of California an incidence of 7.5 per 100,000 inhabitants was reported in 
2007, including 2,726 new cases, more than any other state in the country.  Specifically, the 
City of San Francisco reported 142 new TB cases during the same period (CDC 2008). 
Another study in the same city showed a relapse rate of about 1.0% in TB patients and 9.3% 
in TB-HIV co-infected patients (Nahid, Gonzalez et al. 2007).  These low incidence rates are 
a stark contrast to those from other world regions.  For example, Latin America countries, 
such as Panama, have reported an incidence of 45 per 100,000 inhabitants (WHO 2010)  
However, the major burden of TB worldwide is in Africa and South Asia, which reach 
average incidence rates of 340 and 180 per 100,000 inhabitants respectively (WHO 2007).    
 
III. Immune response to M. tuberculosis infection:  Lung granuloma has been described as the 
hallmark of pulmonary tuberculosis (Ulrichs and Kaufmann 2006). Granuloma is defined as 
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a complex, organized immunological structure comprised of differentiated, interdigitated 
macrophages (also called epithelioid cells) which are surrounded by other immune cells, 
such as T and B lymphocytes and natural killer (NK) cells (Figure 1.1). These cell types are 
organized in a fashion that forms a cellular wall, which prevents the pathogen from 
disseminating throughout the host and focuses the immune response to the site of 
mycobacterial infection.  Development of proper granuloma structure is controlled by 
chemokines and cytokines produced by local tissue cells and infiltrating leukocytes (Ulrichs 
and Kaufmann 2006). In addition, coordinated activation of cells is crucial for productive 
granuloma development and thus for long term containment of the pathogen to the site of 
infection (Ulrichs and Kaufmann 2006).  
For years it was believed that tuberculous granulomas were stable cell structures 
serving to encircle barriers to "wall off material that cannot be destroyed” (Mariano 1995). 
Recently, increasingly more evidence suggests that granulomas are highly dynamic 
structures (Cosma, Humbert et al. 2004; Volkman, Clay et al. 2004; Egen, Rothfuchs et al. 
2008). Once granulomas are established, these structures maintain themselves by cell 
turnover, which involves local proliferation of macrophages and continuous immigration of 
monocytes. Work done by Dannenberg and colleagues in rabbits has shown that the 
constituent granuloma macrophages have a relatively short life span of several days, and that 
the maintenance of the granuloma structure depends largely on monocyte migration within 
the lung (Ando, Dannenberg et al. 1972).  Epithelial cells have been shown to live 3 to 4 
weeks whereas giant cells survive for only a few days (Mariano, Nikitin et al. 1977) 
(Papadimitriou, Memmos et al. 1979). These cell turnovers exert pressure not only on 
intracellular M. tuberculosis but also on the host immune system to maintain proper 
containment of bacteria. As the cells harboring intracellular bacteria die, bacteria are 
released.  The release of bacteria stimulates recruitment of new macrophages and other host 
immune cells to the site of primary infection in order to reinforce and maintain the 
granuloma structure. It has been observed that the granuloma structure is in constant motion 
at the innate and adaptive immunity stages of infection (Volkman, Clay et al. 2004; Clay, 
Volkman et al. 2008; Egen, Rothfuchs et al. 2008). In order for proper granuloma to be 
maintained there must be constant crosstalk between the bacterium and the host immune 
system at the primary site of infection. Successful maintenance of the granuloma leads to 
containment of the pathogen to the site of primary lesion. 
Cavity is a hallmark of advanced stages of TB.  In those individuals with advanced 
TB, the granuloma develops a caseous necrosis center. These caseous necrotic sites enlarge 
and establish communication with the bronchial tree, thus forming a cavity.  The cavities are 
able to access oxygen, allowing the M. tuberculosis bacilli to multiply in high numbers. 
Quantification of the liquefied material within a single cavity has been shown to have 107–
109 bacilli; this indicates that patients with cavitary TB can readily transmit the disease to 
others (Dannenberg 2009). Cavitary TB is identified using chest ray, which reveals cavitary 
lesions.    Further cavity classification is made by measuring the cavitiy’s diameter and 
determining whether cavities are present in both lungs. Cavitary TB is classified according 
to large (>4cm) or small (<4 cm) cavity lesions.  Bilateral cavitary TB indicates the presence 
of cavities in both lungs.   
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IV. Treatment of Tuberculosis: The identification of acid fast bacilli (AFB) in stained 
smears from sputum or other bodily fluids together with clinical and epidemiological 
findings consistent with TB are elements for presumptive diagnosis of active disease and 
usually justify initiation of anti-TB treatment.  For most cases of drug susceptible disease, 
a 6-month regimen is recommended including isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA), and ethambutol (EMB) for the first 2 months followed by INH and 
RIF for 4 months.  Currently, most regions administer this regimen following the 
guidelines under the Direct Observed Treatment Strategy, or DOTS (WHO 2007).  The 
application of this strategy has been shown to be highly effective and reliable in the 
treatment of most infected patients (Singla, Sarin et al. 2009).   
A. Multi-drug resistant tuberculosis: Multi-drug resistant tuberculosis (MDR-TB), 
defined as TB caused by organisms that are resistant to at least INH and RIF, 
threatens the progress made in controlling the disease.  The emergence of extensively 
drug-resistant TB (XDR-TB), defined as MDR-TB that is also resistant to all 
fluoroquinolones and to at least one of three injectable second-line drugs (i.e., 
amikacin, capreomycin or kanamycin), intensifies this threat (WHO 2008).  In 
general, the drug resistant tuberculosis data are limited.  However, since 1994 the 
WHO and the International Union against Tuberculosis and Lung Disease (The 
Union) have conducted global drug resistance surveillance in selected sites.  In the 
2008 WHO/Union Report, the proportion of new cases and/or incidence of resistance 
to any drug increased in Peru, the Republic of Korea, Lithuania, and Russia 
(WHO/IUATLD 2008).  The highest drug resistance proportions and/or rates 
occurred in areas where TB control practices have not been rigorously monitored, 
suggesting that poor TB control practices may be the basis for the high degree of 
drug resistance observed. 
Although treatment for patients with MDR-TB has been available in high-
income countries for many years, this is not the case for resource-limited countries.  
The management of MDR-TB is complex, time-consuming and demanding to both 
the patient and provider.  Thus, it is often recommended that this management be 
implemented only in hospitals equipped with appropriate isolation units, stringent 
infection control measures, multidisciplinary medical teams, and access to high 
quality reference laboratories.  In developed countries such as United States, such 
treatment costs up to $180,000 per case (Moore-Gillon 2001).  The management of 
MDR-TB in resource-limited countries is even more challenging due to limited 
infrastructure, the need for more trained personal, and lack of proper medications. 
Currently, international efforts are being directed at the introduction of MDR-TB 
management programs in low-income countries. The WHO and several partners 
launched the DOTS-plus treatment model in the late 1990’s.  In this model, the use 
of the regular DOTS strategy is complemented with second-line drugs provided at 
concession prices by the pharmaceutical industry.  These drugs are carefully 
introduced and monitored in the health care system and within the framework of 
local TB control programs. This new effort falls under the umbrella of the Green 
Light Committee (GLC).  The GLC acts as an expert review and WHO advisory 
body, which ensures that participating countries are using the standardized regimens 
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along with appropriate health care infrastructure and the technical and financial 
resources of the countries involved.   
The development and implementation of new tools to monitor treatment 
response would strengthen the recently introduced DOTS-plus strategy (Grandjean 
and Moore 2008).  Adequately altering treatment in a timely manner will help to 
limit the spread of MDR-TB and even XDR-TB strains to susceptible populations 
and therefore decrease their incidence. 
 
V. Current state of TB diagnosis: The most common methods for TB diagnosis are the 
observation of AFB smears in sputum and M. tuberculosis growth in cultures from 
sputum.  Developed nations, including the US, also use culture to diagnose TB (2000).   It 
is widely accepted that M. tuberculosis culture  has a higher sensitivity and detection rate 
of pulmonary TB (80%) than smear microscopy (Levy, Feldman et al. 1989).   The 
American Thoracic Society has also indicated that the growth of the organisms is 
necessary for precise species identification; drug susceptibility testing requires culture of 
the organisms; and that genotyping of cultured organisms may be useful to identify 
epidemiological links between patients or to detect laboratory cross-contamination (2000).  
However, sputum culture and AFB smear have certain disadvantages.  Sputum smear has 
poor sensitivity and specificity.  One-half of all new cases of pulmonary tuberculosis are 
smear negative at initial diagnosis and other pathogens can appear as AFB.  During anti-
tuberculosis therapy, the clearance of AFB from sputum is often protracted, and staining 
cannot distinguish viable from nonviable bacilli.  Diagnosis by culture is also problematic 
as the slow growth rate of M. tuberculosis requires up to eight weeks in order to detect a 
culture positive result.  (Desjardin, Perkins et al. 1999). During this prolonged period, the 
culture test can easily be contaminated, further extending the time to report a positive 
diagnosis.  
While the AFB smear is the method recommended by the WHO for low-income 
settings, in more affluent nations, the tuberculin skin test (TST) is widely used for TB 
screening (Farhat, Greenaway et al. 2006).  The TST is used to diagnose latent TB 
infection, but has a relatively low specificity because it cross-reacts with Bacillus 
Calmette-Guérin (BCG) and Mycobacteria other than tuberculosis (MOTT).  The BCG 
strain is used for vaccination in developing countries and MOTT are frequently found in 
environmental sources such as tap water.  This renders the interpretation of a positive TST 
difficult, especially in regions with high MOTT infection rates and BCG vaccinated 
populations (Farhat, Greenaway et al. 2006).  Additionally, the test requires at least three 
days for results and its sensitivity is low in certain groups, such as patients with Acquired 
Immune Deficiency Syndrome (AIDS).  Novel assays which measure IFN! release assays 
(IGRAs) e.g., QuantiFERON TB Gold (Cellestis, Carnegie, Australia), and T-SPOT TB 
(Oxford Immunotech, Oxon, UK) are faster (results can be obtained overnight) and are 
more specific  since these IGRAs use M. tuberculosis specific antigens (Lalvani 2007).  
Nevertheless, there are still unanswered questions regarding the usefulness of IGRAs in 
TB-endemic countries and in high-risk individuals, such as HIV co-infected individuals 
(Andersen, Doherty et al. 2007).    
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Other diagnostic approaches suffer from additional drawbacks.  Methods such as 
flow cytometry, ELISA, and ELISpot assays are restricted to the antibodies that are 
available and the markers chosen are generally selected on the basis of single marker 
studies.  Measuring single molecules is insufficient when studying complex diseases such 
as TB.  
Nucleic acid amplification tests (NAATs) have also been developed for TB 
diagnosis; and several gene targets within the M. tuberculosis genome have been used.  
The accuracy of commercial and in-house NAATs have been analyzed extensively (Pai, 
Flores et al. 2003; Pai, Flores et al. 2004; Flores, Pai et al. 2005; Ling, Flores et al. 2008).  
Overall, both commercial and in-house NAATs have estimates of accuracy that are highly 
heterogeneous.  In the meta-analysis of 84 studies conducted by Flores et al., results 
indicated that NAAT sensitivity ranged from 9.4% to 100%, and specificity varied from 
5.6% to 100%.  A similar meta-analysis by Ling et al found similar results to Flores et al.  
suggesting that commercial NAATs alone cannot be recommended to replace conventional 
tests for diagnosing pulmonary TB.  In addition, NAATs positive results only reveal 
whether or not there is M. tuberculosis bacilli in a given sputum sample and do not 
indicate additional details about the physiopathology status of the infected host.  Of 
course, NAATs are very helpful in diagnosing AFB negative TB patients and 
extrapulmonary TB.  Overall, the use and application of NAATs has a limited and very 
specific benefit for TB diagnosis and control. !" #$%$&'()" *$+$(,-$*" !"# $%$&# '(# )*+!,-*.&/%/# .$&$" /0-(121%/'1,&" '$3'"45$&$6-$#'"789:;<=>" %/&" /(3," ?$" @3$*" '," *1/.&,3$" *#@.A#$313'/&'" 89B" " 5$&$6-$#'"789:;<=" 13" ?/3$*" ,&" /@',0/'$*" 3/0-($" -#,%$331&." /0-(121%/'1,&" ,2" 'C$" '(#

New diagnostics for tuberculosis are urgently needed to replace or facilitate the use 
of AFB smear and culture tests in the clinical management of patients with pulmonary TB 
(Foulds and O'Brien 1998).  The global control of TB requires the use of more sensitive 
tools for rapid detection of active disease, monitoring treatment, and differentiating latent 
TB infection (LTBI) from active forms of the disease. Improved technologies such as 
GeneXpert MTB/RIF might be useful for reference laboratories and general hospitals, but 
may not be practically applied in low-resources settings where funds for TB control 
programs and technical capacity are limited (Grandjean and Moore 2008). 
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"
A. Pitfalls in monitoring TB treatment response:  Immediate treatment of patients 
with pulmonary TB is effective in controlling the spread of disease.  Once the TB 
patient initiates the drug therapy, he or she becomes less contagious to other close 
contacts.  The TB transmission is then blocked and no new individuals are infected.  
However, the TB treatment is 6 months long and several factors interfere with 
achieving therapy success.  Lack of treatment compliance by the patient and 
intermittent availability of anti-TB drugs in low resource settings contribute to this 
difficulty with treatment success.   In order to avoid treatment failure, it is strongly 
recommended to monitor the therapy of patients with pulmonary TB.  . 
The monitoring of treatment response is based on the evaluation of 
symptoms, monthly sputum smear microscopy and culture conversion.  AFB sputum 
smear evaluation usually occurs at 1, 2, 5 and 6 months after treatment initiation. The 
clearance of AFB from sputum has low sensitivity, is often protracted, and staining 
cannot distinguish viable from nonviable bacilli.  The conversion of a culture from 
positive to negative 1 to 2 months after the start of treatment correlates with the 
sterilizing activity of the drugs administered and is considered the best predictor of 
treatment success.  However, because of the slow growth rate of M. tuberculosis, this 
measure can be determined only after weeks or months of treatment (Desjardin, 
Perkins et al. 1999). Treatment monitoring by serial chest radiographs is also not 
recommended. Radiological abnormalities may persist for months after a good 
treatment response, often due to permanent scarring.  However, performing an end-
of-treatment (EOT) chest X-ray in patients with pulmonary TB is recommended in 
order to establish a new baseline of the patient’s anatomy to serve as a reference in 
case of relapse or re-infection.   
The use of AFB smears with low sensitivity and delayed bacterial culture 
conversions for monitoring treatment have hampered the effort for TB control 
worldwide.  These circumstances make treatment monitoring a challenging task and 
as a result, health care professionals have to rely mostly on clinical expertise and 
available epidemiological data to determine treatment effectiveness (Heymann 
2004).  This situation calls for the development of tests that will allow for efficient 
clinical management of patients undergoing treatment for pulmonary TB.  This 
dissertation presents the discovery, research and validation of a new biomarker-based 
test to monitor anti-TB treatment response.  
 
VI. Rationale for using a biomarker-based test:  Most TB diagnostic and prognostic tests 
are based on detection of pathogen signals.  In most cases, these types of tests are specific 
and sensitive.  However, the technologies designed to enhance detection of pathogen 
signals become more expensive and often require ever-more complicated technology.  
This situation poses a huge challenge when trying to implement these tests in low resource 
settings.  Indeed, the major burden of TB is located in areas where economical resources 
and science and technology capabilities are sparse.  Thus, many of the TB control 
programs are not able to purchase expensive cutting-edge technology to run their diagnosis 
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and prognosis activities.  In addition, it is likely that the laboratory personnel in those areas 
do not have training and are not in touch with the current pipeline test.    
The alternative to pathogen signal detection is biomarker detection.  These tests are 
often simpler, cheaper and affordable for immediate implementation in high burden 
settings located in remote areas.  In addition, biomarker-based tests are easily transformed 
into point of care devices, completely portable and with minimal technological 
requirements.  This facilitates the use and application not only for TB control program 
activities but also for vaccine development, clinical trials and monitoring the treatment 
response.  Indeed, Walzl et al recently highlighted the need for host biomarkers to 
diagnose TB and provide correlates of risk of TB (Walzl, Ronacher et al. 2008; Walzl, 
Ronacher et al. 2011).  We believe that shifting the global effort against TB to the 
development, implementation and use of biomarker-based tests will have a major impact 
in TB control worldwide.  
 
A. Biomarker definition: Biological indicators or biomarkers generally include 
biochemical, molecular, genetic, immunological or physiological signals of events in 
biological systems (NATIONAL-RESEARCH-COUNCIL 2006). These events are 
depicted as a continuum between an exposure to a microbial infection and the 
resulting clinical effect.  Biomarkers traditionally have been classified as indicators of 
exposure or susceptibility to a disease or condition.  For the purposes of the present 
study, we are interested in biomarkers of effect, e.g., biomarkers that measure 
biochemical, physiologic, behavioral, or other alterations in the host that, depending 
on magnitude, can be recognized as associated with an established or possible health 
impairment or disease.  Moreover, we are interested in using the antibody response to 
specific M. tuberculosis lipids (effect) as a biomarker of the infection stage in patients 
undergoing treatment.  In this case, the antibodies are a characteristic that can be 
objectively measured and evaluated as indicators of active disease and therefore meet 
the current biomarker definition (GROUP 2001; Jacobsen, Mattow et al. 2008).  
 
B. Use and application of biomarkers in TB.  As mentioned above, the identification of 
biomarkers has been the major focus of global efforts against TB in recent years.  This 
search has lead to the identification of a wide variety of biomarkers that can 
potentially be used in TB diagnosis and treatment monitoring.  Most biomarkers are 
based on the detection of M. tuberculosis or its products, as well as the detection of 
products from the host’s immunological response during active disease or latent 
infection.  The exact application will depend on the nature of the biomarker and 
subsequent validation in clinical studies.  To date, few biomarkers have proven 
effective for assessing all stages of TB and in most cases, biomarkers have a single or 
dual application.  Recently, Walzl et al revised the immunological biomarkers 
available to study TB (Walzl, Ronacher et al. 2011).  They emphasized that the 
identification of biomarkers is highly dependent on our understanding of tuberculosis 
pathogenesis.  Indeed, the marked heterogeneity of the host immune response and 
bacterial metabolism within the infected host will influence the validation of 
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biomarkers to study different TB stages.  With this in mind, the discovery and 
identification of a biomarker-based test can be separated into four methods of use: 1) 
diagnosis of active disease; 2) differentiation of active disease from LTBI; 3) 
prediction of progression from LTBI to active disease and 4) monitoring treatment 
response.  The correct application of a TB biomarker for any of these uses will require 
a stepwise identification process as well as strict clinical validation studies.  
Biomarker-based tests using a combination of molecular profiles will likely 
have higher power than a single molecule (Immunodiagnosis Conference 2008; Wazl 
et al 2008 review).  Such increased power is necessary to characterize the disease 
status of an individual receiving TB treatment.  Sufficient characterization of a 
patient’s disease status would allow for correct classification of individual therapy 
stages.  Thus, monitoring biomarkers will properly indicate recovery as well as 
therapy responsiveness within different patients (Jacobsen, Mattow et al. 2008) 
facilitating appropriate follow-up for TB patients during drug therapy. 
  The specific uses of biomarker-based tests will vary depending on the 
stage of TB infection.  The diagnosis of active disease requires biomarkers to rapidly 
identify contagious individuals.  This is a key element that contributes to the efforts 
for stopping TB transmission.  On the other hand, differentiation between active and 
LTBI assumes that biomarkers are able to reflect the undergoing physiopathology of 
infection within the lung (Walzl, Ronacher et al. 2011).  Because of this, cytokine 
release assays (CRA) have provided a more sensitive and specific biomarker-based 
test than the TST.  However, the role of CRA in high incidence areas has not been 
determined yet.  Detecting progression from LTBI to active disease requires 
biomarkers with higher discriminatory power.  For example, the widely used 
interferon gamma release assay has a large intermediate range, where results cannot be 
determined as positive or negative.  These ambiguous results create uncertainty for the 
clinician and increase the cost of TB control programs by increasing the number of 
test repeats in order to observe a positive result.   
Finally, the response to anti-tuberculosis treatment requires a novel biomarker-
based test with three potential applications.  First, pretreatment biomarkers with 
predictive ability could identify the requirements of individual patients for specific 
treatment regimens.  Second, early treatment response biomarkers could confirm the 
effectiveness of anti-tuberculosis therapy for both clinical management and within 
clinical trials for new drugs.  Third, an end of treatment biomarker for relapse could 
facilitate the evaluation of shortened drug regimens in clinical trials.  These potential 
applications demonstrate the need for discovery and validation of novel biomarkers to 
increase the repertoire of tests available for improved TB clinical management.  
 
C. Lipid-antibody biomarker: It has been previously described that a large proportion 
of the M. tuberculosis genome is dedicated to the synthesis and catabolism of lipids 
and a large proportion of the cell wall consists of complex lipids (Brennan and 
Nikaido 1995; Senaratne, Sidders et al. 2008; Dunphy, Senaratne et al. 2010).  The 
plasma membrane of Mycobacterium contains phospholipids found in other bacteria as 
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well as numerous lipids unique to Mycobacterium, notably, 2-alkyl-3-hydroxy fatty 
acids made up of up to 90 carbons.  Other lipid-containing molecules unique to the M. 
tuberculosis complex are phenolic glycolipids, polyacyltrehalose and 
lipooligosaccaharides (Brennan and Nikaido 1995).  These different mycobacterial 
lipids are preferentially distinguished by the immune system at several levels. For 
instance, lipoarabinomanan lipids represent an antigen recognized by Toll-like 
receptors of the innate immune system.  Other lipids are presented by the CD1 
molecules to T lymphocytes such as the mycolic acids and glucose monomycolates 
(Lang and Glatman-Freedman 2006).  Because of their unique presence in 
mycobacteria, these lipids provide a valuable biosignature useful to identify host 
biomarkers. (Jacobsen, Mattow et al. 2008)  
Recently it has been shown that lipid molecules can activate T lymphocytes 
through their presentation by CD1 molecules (De Libero and Mori 2005; Mendelson, 
Walters et al. 2005; Lang and Glatman-Freedman 2006; De Libero and Mori 2008).  
These lipid molecules act as antigens capable of inducing IgM, IgA, and IgG antibody 
humoral responses.  As opposed to peptide antibodies, which are generated by B-2 B 
cells, the lipid antibodies are mainly produced by B-1 B cells, which represent about 
5% of the entire B cell population (Figure 1.2).  In general, the B-1 B cells are very 
different from B-2 B cells since the former have very little or no memory and they are 
mainly located in pleural and peritoneal cavities.  B-1 B cells express high levels of 
IgM and do not require T cell help as they self-renew from pre-existing B1 cells.  
Interestingly, these cells lack somatic hypermutation and have restricted diversity in 
the V region (Kindt, Goldsby et al. 2007).  B-1 B cells can differentiate into two 
distinctive lineages including B1a and B1b B cells each with a distinctive phenotype 
(Tung, Mrazek et al. 2006). The characteristics of these B-1 B cell suggest that the 
antibodies produced by B-1 B cells contribute to the innate immunity of the host that 
is stimulated by the active infection status in the host. 
  We propose that B-1 B cell-related humoral responses might be used as 
biomarkers of infection because the level of antibody response to M. tuberculosis 
lipids may correlate with bacterial burden during infection.  Specifically, we 
hypothesize that the antibody response to lipids may decrease with successful 
treatment as the bacterial load decreases in the infected host.  Such change, therefore, 
could serve as a marker for a positive response to treatment.  In fact, this method 
closely emulates the technique for monitoring response to syphilis treatment.  Syphilis 
is a disease for which the etiologic agent cannot be artificially grown in the laboratory, 
and will be discussed further in the rationale below. 
 
D. Biomarker focus of this dissertation: The use of antibody responses to lipids as a 
biomarker for monitoring treatment response is an established practice. As mentioned 
above, the classic example of this approach is syphilis treatment, in which “natural” 
antibodies to lipids are measured to determine the effectiveness of the treatment. The 
traditional approach to syphilis serodiagnosis has two steps.  The first step involves 
screening with a non-treponemal test such as the rapid plasma regain test (RPR). This 
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is followed by a confirmatory testing of the reactive specimens using a treponemal test 
such as the Treponema palladium particle agglutination assay (TPPA) (Peeling and 
Hook 2006).  Interestingly, the non-treponemal test -RPR- usually reverts to negative 
after treatment with penicillin in contrast to the treponemal tests.  For that reason, the 
RPR is extensively used to monitor the effectiveness of the syphilis treatment given 
the fact that the specific tests (protein-based), such as the TPPA, remain positive 
indefinitely after the early or late stage of the disease (Lee and Kinghorn 2008).  More 
specifically, the non-treponemal test (RPR) measures the IgM and IgG antibodies to 
lipoidal material released by damaged host cells, lipoprotein-like material, and 
possibly cardiolipin released from the treponemes.  These antibody titers were shown 
to decline four-fold by the third month, and continued to decline to an undetectable 
level after the first year of treatment (Larsen, Steiner et al. 1995). 
VII. Closing remarks 
  Lipid-antibody biomarker-based tests are reasonable alternatives to monitor anti-TB 
therapy.  Until now, the antibody response has only been used for diagnosing TB in humans.  
Recent evidence shows there is a wide repertoire of antibody responses during active disease.  
However, the utility of the lipid-antibody response to monitor TB therapy still remains unknown.  
The dissertation research results presented here delineate the discovery, biological understanding 
and validation of a lipid-antibody biomarker useful for monitoring treatment response in 
mammalian hosts.   The results given provide the foundation for a new type of test that could 
contribute to TB control worldwide. The evidence presented here also contributes to our 
understanding of the lipid-antibody biology, which could allow others to identify new areas 
where they can be applied.     
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Figure 1.1. A cellular tuberculosis granuloma. An inner core of 
epithelioid macrophages (larger light pink cells in the center) is 
surrounded by an outer ring of lymphocytes and neutrophils (smaller dark 
purple cells).  The arrow indicate the area of accumulation of T cells. 
Hematoxilin and Eosin stain at 20X objective. 
 
 
 
VIII. Figures 
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Figure 1.2.  Developmental precursors of B-1 and B-2 cell.  Note that depending 
on the signal from B Cell Receptor (BCR), Notch-2 receptor and B cell Activation 
receptor (BAFF), the precursor can be differentiated into B-1a, B-1b, MZ or B-2 B 
cells.  
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CHAPTER 2 
Lipid-antibody screening and identification 
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I. Introduction 
The identification of a lipid-antibody biomarker suitable for monitoring TB treatment 
response involves two key elements from both the pathogen and the host: 1) the screening of 
lipid candidates from M. tuberculosis and 2) the array of humoral responses in the infected 
host.  Both elements are complex and identifying the useful components requires a high 
throughput screening strategy.  For instance, M. tuberculosis harbors a wide variety of lipid 
molecules that can be used as an antigen.  These lipids can be found in the cell wall or 
cytoplasm and may differ according to the growth stage of the bacteria. The host will respond 
differently to M. tuberculosis infection depending on his/her immunological status, 
nutritional levels, previous exposure, and even ethnic background.  Thus, the search for a 
lipid antibody candidate appropriate for both the pathogen and host immune system can 
consume valuable time and financial resources.  For these reasons, we screened crude M. 
tuberculosis lipids by a new method of thin layer chromatography-immunoblot (TLC-I).  
This method allowed us to determine which mycobacterial lipids could be used as a basis for 
a biomarker test to monitor treatment response.  This chapter shows the preliminary data 
obtained using this approach.  
Our findings suggest that the antibody response against M. tuberculosis lipids varies 
during different stages of TB infection.  First, we used an in vivo mouse model based on the 
Cornell animal model of TB infection, and second, we compared the presence of antibodies 
in serum samples drawn from humans that were AFB smear positive TB patients, non-TB 
patients or healthy controls.  The non-TB group included patients with pneumonia caused by 
pathogens other than M. tuberculosis.  In this way, we were able to identify the lipid antigens 
to which antibodies can be used as a biomarker of anti-tuberculosis treatment response.  
 
II. Methods 
A. TLC-I lipid screening in Cornell mouse model: BALB/c mice were infected via 
inhalation of aerosolized M. tuberculosis H37Rv reference strain. At 4 weeks 
post-infection, half of the mice were treated for 8 weeks with antibiotics (INH and 
PZA) ad libitum.  Treatment led to a state of infection in the mice where bacilli 
could not be recovered from any of the organs by culture on 7H9 agar plates.  
Blood was collected from the mice at day 1 and at week 12 post-infection (p.i.) to 
study the antibody response to multiple M. tuberculosis lipids resolved by TLC.  
All experiments with animals were approved by the ACUC Animal Use Protocol 
# R228-1211B. 
In brief, M. tuberculosis H37Rv (ATCC #27294) reference strain was cultured 
in 7H9 liquid media for 14 days at 37°C without CO2.  Total lipids from packed 
bacterial cells were extracted for two hours with chloroform:methanol (2:1, v/v).  
Bacterial debris were separated by centrifugation and the supernatant containing 
the lipids was stored at  
-80°C until use or evaporated under nitrogen gas and dissolved in 300µl 
chloroform:methanol (C:M) (2:1, v/v) for application in TLC-I. 
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A 20µl volume of extracted lipids was spotted onto a silica gel 60 plate and 
separated in a chromatography chamber with solvent systems including 
C:M:(CaCl2)=65:35:7.  A set of the separated lipids was revealed by 
phosphomolybdic acid.  Another set of separated lipids was fixed with 0.5% 
polyisobutylmethacrylate.  The subsequent immunoblot was performed by first 
blocking the TLC plate with 3% bovine serum albumin in phosphate buffer saline 
(BSA-PBS) and then incubating the plate with a 1:100 dilution of mouse serum in 
BSA-PBS 3% overnight at 4ºC (Fujita, Doi et al. 2006).  The TLC plate was then 
washed with PBS six times for 10 minutes each time.  Immediately after washing, 
the TLC plate was incubated with a 1:50,000 dilution of rabbit anti-mouse IgG-
HRP for 2 hours at room temperature (RT) and washed with PBS six times for 10 
minutes each time.  Finally the TLC-I was developed with enhanced 
chemiluminescence (ECL) autoradiography with a substrate from Pierce Thermo 
Fisher Cat No. 34087 (Rockford, IL, USA).  
B. TLC-I screening in patients with pulmonary TB and pneumonia: A set of 20 
serum samples was obtained from the World Health Organization-Tropical 
Diseases Research (WHO-TDR) serum bank (Nathanson 2008).  This set of 
samples included 10 patients with pulmonary symptoms suggestive of pneumonia 
other than TB (non-TB patients) and 10 patients with pulmonary TB diagnosed by 
AFB smear, culture and chest X-ray (TB patients).  A third group included 20 
samples from healthy individuals was obtained commercially from Equitech-Bio 
Inc (Kerrville, TX, USA). These individuals did not have any pulmonary 
symptoms, cough or fever, and were negative for HIV, hepatitis B and C, syphilis, 
Chagas disease, and West Nile, per FDA regulations.  Additional information 
about the epidemiological data and risk factors of the patients are included with 
the data set.  All serum samples were received frozen, thawed once on ice, split 
into small aliquots, and frozen again for further use in the TLC-I. Samples did not 
experience thaw-freeze cycles as they were maintained in cold chain to ensure 
sample quality before arrival at the UC Berkeley laboratory (Nathanson 2008)   
IRB approval was obtained from the committee for protection of human subjects 
(CPHS) at UC Berkeley 2010-02-791. 
C. Thin layer chromatography immunoblot (TLC-I): Mycobacterial lipids were 
prepared as described above for the animal model. Extracted lipids were spotted 
in a silica gel 60 plate and separated using the same conditions described above.  
TLC plates were then incubated with a 1:1000 dilution of patient serum (vs. 1:50 
dilution used for mice) in 3% low fatty acid bovine serum albumin (LFA-BSA) 
overnight at 4º C.  The TLC was then washed with PBS six times for 10 minutes 
each time.  The TLC plate was immediately incubated with a 1:50,000 dilution of 
goat anti-human conjugated IgM-HRP for 2 hours at RT and washed with PBS six 
times for 10 minutes each time.  The TLC-I was developed using enhanced 
chemiluminescence autoradiography with a substrate from Pierce Thermo Fisher 
Cat No. 34087 (Rockford, IL, USA). 
D. Lipid identification by mass spectrometry: The lipid antigen within the TLC-I 
profile of interest was identified by a stepwise wet chemistry procedure.  Briefly, 
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mycobacterial lipid extracts were fractionated by silica column chromatography.  
Lipid fraction F6 containing lipids that migrated to the same location as our lipid 
band of interest in the TLC-I (Rf=0.6) were selected for further identification.  
TLC-I was performed to confirm the IgM antibody response to fraction F6 
(Figure 2.4). The lipid fraction was then dried under nitrogen gas flow and 
reconstituted in chloroform:methanol (1:1).  Mass spectrometry (MS) and tandem 
mass spectrometry (MS/MS) measurements were performed by quadruple time-
of-flight (Q-tof Premier, Waters, Milford, MA) and LTQ Orbitrap XL (Thermo, 
Waltham, MA) instruments.  Mass spectra were recorded with electrospray 
ionization in the negative ion mode.   
E. Lipid-protein overlay assay (LPOA):  Commercial nylon strips with cell 
membrane lipids were obtained from Echelon Biosciences Inc Cat. No. P-6002 
(Salt Lake City, UT, USA).  Each strip membrane had 15 spots with the following 
synthetic cell membrane lipids: trigliyceride (TG), diacilglycerol (DAG), 
phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylglycerol (PG), cardiolipin (CL), 
phosphatidylinositol (PI), phosphatidylinositol phosphate (PI-4-P), 
phosphatidylinositol diphosphate (PI-4,5-P), phosphatidylinositol triphosphate 
(PI-3,4,5-P), cholesterol (CHOL), sphingomyelin (SM), 3-
sulfogalactosylceramide (SG), and one blank solvent spot (Figure 2.6).  WHO-
TDR and healthy control serum sample sets were analyzed using modifications of 
the manufacturer’s protocol.  Briefly, strips were blocked with 3% low fatty acid 
bovine serum albumin (LFA-BSA) for one hour.  Lipid strips were then washed 
once with phosphate buffer saline (PBS) at RT.  The strips were then incubated 
with a 1:1000 dilution of patient serum in 3% LFA-BSA overnight at 4ºC.  Next, 
the strips were washed with PBS twelve times for five minutes each time at RT 
and immediately incubated with a 1:20,000 dilution of goat anti-human 
conjugated IgM-HRP for 2 hours at RT.  The nylon strips were then washed with 
PBS 18 times for 5 minutes.  The strip was developed with enhanced 
chemiluminescence (ECL) autoradiography with a substrate from Pierce Thermo 
Fisher Cat No. 34087 (Rockford, IL, USA).  
E.  Statistical Analysis: The presence of IgM in the TLC-I and LPOA assays in TB, 
non-TB and HC groups were compared by Fisher Exact test using a two way table 
analysis.  Data are presented in percentages.  Comparisons were considered 
significant with p < 0.05. 
 
III. Results 
A. TLC-I lipid screening in Cornell mouse model: Differences were observed in 
antibody response between treated and untreated mice during the course of 
infection.  Antibodies against some mycobacterial lipids were not detectable at 
day 0 of the infection (Figure 2.1).  After the eighth week of treatment (12 weeks 
post-infection) there were differences in the TLC-I patterns shown in treated and 
untreated mice (Figure 2.2).  At this time point, the untreated mice showed 
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signals of a strong antibody response to some of the mycobacterial lipids, whereas 
treated mice showed decreases in antibody response to the same mycobacterial 
lipids.  These differential results also correlated with the bacterial load in the 
lungs of infected mice, with the treated mice showing lower numbers of M. 
tuberculosis colony-forming units (CFU) than untreated mice at the same time 
point.  
In order to determine if the differential response observed by the TLC-I 
method in the mouse experiment is appropriate for monitoring the response to 
treatment in a human host, we used human serum to examine the lipid antibody 
response in 1) those with active TB disease before treatment, 2) those with 
pulmonary disease other than TB, and 3) healthy individuals.   
 
B. TLC-I screening in patients with pulmonary TB and pneumonia: Our 
preliminary results showed differences in antibody response to polar lipid 
fractions between TB patients and non-TB patients.  IgM antibodies against some 
mycobacterial lipids were not detectable in non-TB patients.  In contrast, the 
TLC-I showed a different banding pattern in the serum of TB patients, with a 
strong IgM antibody response to several mycobacterial polar lipids.  The banding 
pattern indicated that an IgM antibody response to polar lipids occurred 
significantly more frequently in the TB patient serum (100%) versus the non-TB 
patient serum (60%) (p=0.043 Fisher Exact test) (Figure 2.3).  These results 
suggest that the detection of anti-mycobacterial polar lipid IgM antibodies by 
TLC-I may serve as a potentially useful biomarker test for monitoring TB 
treatment response.  The application of these IgM antibodies for diagnosis 
purposes might be beneficial. 
 
C. Lipid identification by mass spectrometry: The mass spectra exhibited a doubly 
charged negative ion at m/z = 701 and a singly charged negative ion at m/z = 1404 
(Figure 2.5).  The accurate mass measurements of these ions, in combination with 
MS/MS measurements, identified this lipid as cardiolipin (C77H146P2O17).  These 
results suggest that this lipid was the main target of IgM antibody response in the 
studied fraction. 
 
D. Lipid-protein overlay assay (LPOA) screening:  Since cardiolipin is a member of 
the phospholipid family, we hypothesized that other phospholipids would elicit a 
similar IgM antibody response in TB patients.  We looked for commercial sources 
of phospholipids that are known to be present in the cell wall of M. tuberculosis 
and used them to test for the presence of these antibodies during active disease.  
 TB patients have higher levels of IgM antibodies against bovine 
cardiolipin.  Among the cell membrane lipids in the LPOA strip, IgM antibodies 
against cardiolipin were found in 89% of TB patients from the WHO-TDR sample 
set (Table 2.1, Figure 2.7).  This was significantly higher than the percentage of 
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healthy controls with the IgM antibodies (17%), but not significantly different 
from non-TB pneumonia patients (78%).  IgM antibodies against cholesterol and 
sphingomyelin were also found in significantly higher proportions of TB patients 
compared to healthy individuals. The 12 remaining synthetic cell membrane lipids 
showed no significant differences when comparing all three groups. There were 
non-significant differences between the AFB positive patients and the non-TB 
pneumonia group for the cell wall lipids including TG, DAG, PA, PS, PE, PC, 
PG, PI, PI-4-P, PI-4,5-P and SG.  No additional trend was observed within these 
non-significant lipids for the AFB group vs. the non-TB group.  
 
IV. Discussion  
The above experiments show differential antibody response against M. tuberculosis 
lipids in serum from infected and uninfected hosts.  Both murine and human experiments 
showed that there is an increased lipid-antibody response in these hosts during TB infection.  
Specifically, mice that were infected with M. tuberculosis showed higher antibody levels 
compared to mice that received anti-tuberculosis treatment.  Similarly, human hosts infected 
with TB also showed higher antibody signals in the TLC-I screening test compared to hosts 
with non-TB pneumonia, indicating IgM type antibodies as a potential biomarker for 
untreated TB infection.  TLC-I analysis showed no consistent pattern within the IgG and total 
Ig antibodies from the human serum samples.   
Unlike humans, mice have only one (CD1d) of the 5 known subtypes of CD1 
molecules (CD1a-e).  Therefore, mice may not be as efficient as humans in presenting lipid 
antigens.  Thus, the above results are only a starting point from which to identify an 
appropriate lipid-antibody biomarker useful for monitoring treatment in humans. 
The IgG antibody response for lipid antigens has been described as very diverse, 
which could relate to the poor utility of IgG as a marker for diagnosing TB (Steingart, 
Dendukuri et al. 2008).  Perhaps IgG antibody produced during TB is secreted not only by B-
2 B cells, but also by marginal zone (MZ) cells, which have both B-1 and B-2 B cells 
properties.  This situation would alter any antibody response associated with TB lipids.  In 
addition, the portion of IgG detected by the TLC-I may be produced by memory B cells and 
not related to the infection status in the lung of TB patients.  Unlike IgG antibodies, IgM 
antibodies, especially those generated by B-1 B cells, showed a consistent pattern with the 
TLC-I screening.  This allowed us to pursue and identify which of the lipids associated with 
these patterns could be tested as a biomarker to monitor the TB treatment response.  
Cardiolipin (CL) from M. tuberculosis was identified as the major lipid antigen from 
our antibody biomarker test using mass spectrometry from a TLC eluate and a column 
chromatography fraction.  Our experiments showed that the M. tuberculosis CL antigen is 
capable of distinguishing patients with TB from those with non-TB pneumonia.  These 
findings allowed us to rapidly assess commercial sources of this and other lipids with similar 
structures for further evaluation as a biomarker test to monitor TB treatment response.  The 
next chapter will describe the biological basis of this anti-lipid response, focusing on what is 
known about the role of B-1 B cell activation and secretion of IgM antibodies during TB and 
anti-TB therapy in animal models.   
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Analysis of the human serum samples using the LPOA showed that TB patients have 
significantly higher IgM antibody levels to cell membrane lipids, including cardiolipin, 
cholesterol, and sphingomyelin, than healthy individuals (Table 2.1).  High levels of anti-
cardiolipin IgM antibody were also present in 78% of non-TB pneumonia patients.  
However, there were no significant differences in these antibody levels between non-TB 
patients and the TB patients within the WHO-TDR sample set.  The different phospholipid 
antigens in the nylon strip membrane might explain these results.  While the TLC-I uses total 
lipids extracted from M. tuberculosis, the LPOA uses a set of synthetic lipids produced from 
theoretical structures, making the commercial LPOA incomparable with our TLC-I screening 
tool.  However, the former test provides evidence that support our initial TLC-I findings in 
the human and animal studies.  Indeed, the LPOA results correlate with the previous 
identification of CL in eluate of TLC-I by mass spectrometry, indicating that TB patients 
have higher levels of IgM antibody against CL originating from the M. tuberculosis cell 
membrane.   
The CL structure from bacteria and bovine are similar. Previous studies have shown 
that CL has four fatty acid chains and two polar heads with the phosphate group linked by an 
acyl chain (Jensen, Tomer et al. 1987; Gutberlet, Dietrich et al. 2000). The only difference 
between bacterial and bovine CL is the number of double bonds within the fatty acid chain.  
CL from E. coli has only two double bonds, whereas bovine CL has two double bonds per 
fatty acid chain, for a total of eight double bonds.  The structure of M. tuberculosis CL has 
not been described yet.  Our study describes the mass spectrum suggestive of CL molecules 
found in the eluate of the TLC of M. tuberculosis H37Rv lipids.  The exact structure and 
double bond locations still remain unknown and require additional characterization by 
nuclear magnetic resonance (NMR) strategies.  However, it is not understood if variations in 
the number of double bonds accounts for the antibody affinity difference.  Reis et al 
demonstrated that fatty acid chains with double bonds are highly susceptible to oxidation 
(Reis, Domingues et al. 2004).  Other groups have shown that natural antibodies have a 
higher affinity to oxidized cardiolipin and oxidized lipid transporter molecules such as LDL 
(Tuominen, Miller et al. 2006; Gounopoulos, Merki et al. 2007; Chou, Hartvigsen et al. 2008; 
Chou, Fogelstrand et al. 2009; Binder 2010).  Taken together, this evidence suggests that 
bovine CL is a good surrogate lipid to use as an antigen to detect IgM antibodies in TB 
infected humans.  If the IgM antibody levels show changes over the course of infection, this 
lipid antibody biomarker will be a suitable tool to monitor the treatment response during anti-
TB drug therapy.  M. tuberculosis CL is not commercially available and difficult to purify.  
Thus, we proposed to use bovine CL and other similar phospholipids to determine the IgM 
antibody levels during TB treatment in human and animal hosts.  In Chapter 3 we will 
discuss anti-phospholipid IgM antibody biomarkers and the biology behind the secretion of 
these anti-phospholipid IgM antibodies in infected mice.   
Together these results indicate that cardiolipin, either from M. tuberculosis or from 
commercially available sources, are suitable biomarker targets for TB and can potentially be 
used to monitor TB treatment response.  Since the techniques used to identify CL as a 
biomarker are based on the intensity of chemioluminiscence, we were not able to quantify the 
exact amount of antibodies involved in host response.  A quantitative method such as ELISA 
should be used to determine relative quantitative differences in the level of antibodies present 
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in these patients during treatment.  Chapter 3 and 4 will describe findings for the 
quantification of anti-phospholipid IgM antibody during treatment of acutely and chronically 
infected mice, as well as during the intensive phase of treatment in humans. 
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V. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1a:  TLC stained with phosphomolybdic acid before the TLC-I.  Figure 2.1b: TLC-I of 
mouse serum at day 0 of infection (uninfected mice) using different solvent systems: A= C:M:W 
=100:14:0.8, B= C:M:W = 60:30:6, C= C:M:CaCl2 = 65:35:7.   
Figure 2.2a:  TLC stained with phosphomolybdic acid before the TLC-I.  Figure 2.2b: TLC-I of 
mouse serum at 12 week after infection from treated (T) and untreated (UT) animals using 
different solvent system: A= C:M:W =100:14:0.8, B= C:M:W = 60:30:6, C= C:M:CaCl2 = 
65:35:7. 
 
 
 
A    B    C 
Un-infected 
mice 
Fig. 2.1b 
A     B    C 
Untreated 
mice 
Treated 
mice 
Fig. 2.2b 
 A     B    C A     B    C 
A    B  C   
ccc C 
A   B   C 
Fig. 2.2a Fig. 2.1a 
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Figure 2.3: TLC-I with human samples:  Mycobacterial lipids were spotted onto silica gel 
plates and separated by C:M:CaCl2 = 65:35:7 as a solvent system.  The TLC plate was incubated 
with serum samples from TB-patients (left panel) and non-TB patients (right panel), washed, 
and followed by a second incubation with goat anti-human IgM-HRP.  Lanes A through E each 
show an individual TB patient and lanes F through G each show an individual non-TB patient.  
These reactions were developed by chemiluminescence autoradiography.   
 
A     B    C     D     E 
TB patients 
F     G    H     I     J 
non-TB patients  
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Figure 2.4: Confirmatory TLC-I: Whole lipid extract of Mycobacterium 
tuberculosis (lanes 1 and 3) and lipid fraction F6 (lanes 2 and 4) and were 
spotted and onto silica gel plates and separated by C: M:CaCl2 = 65:35:7 as a 
solvent system.  The TLC plates was incubated with serum samples from 
healthy individuals (lanes 1 and 2) and TB-patients (lanes 3 and 4), washed, 
and followed by a second incubation with goat anti-human IgM-HRP.  The 
reactions were developed by chemiluminescence autoradiography.   
 
1     2    3   4 
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Figure 2.5:  Tandem mass spectrum of lipid biomarker candidate in fraction F6:  
M. tuberculosis lipid fraction F6 was dried and resuspended in C:M (1:1) and analyzed 
by tandem mass spectrometry in negative ion mode.  Graph shows tandem mass 
spectrum resulting from collision-induced dissociation of a doubly charged negative 
ion at mass-to-charge ratio (m/z) 701.5.  The identified CL has two fully saturated C16 
fatty acid chains, and two C18 fatty acid chains each containing one unit of 
unsaturation.  The singly charged fragment ions at m/z 391 and 417 are secondary 
fragmentation products, namely, resulting from cleavage at phosphate and loss of C16 
and C18 fatty acid chains, respectively.  Residual precursor ion (m/z 701.5) is denoted 
by the asterisk. 
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Table 2.1: Presence of IgM antibodies against cell wall lipids in TB, non-TB and HC.  
Self 
Lipid 
AFB(+) 
N=9 
% 
Non-TB 
N=9 
% 
HC 
N=18 
% 
AFB(+)  vs 
non-TB 
P value 
AFB(+) vs 
HC 
P value 
TG 0 0 6 n.s. n.s. 
DAG 33 0 0 n.s. n.s. 
PA 22 33 67 n.s. n.s. 
PS 56 56 100 n.s. n.s. 
PE 11 44 0 n.s. n.s. 
PC 11 11 0 n.s. n.s. 
PG 100 100 89 n.s. n.s. 
CL 89 78 17 n.s. 0.0001 
PI 100 89 83 n.s. n.s. 
PIP 89 89 61 n.s. n.s. 
PIP2 0 11 0 n.s. n.s. 
PIP3 11 22 0 n.s. n.s. 
CHOL 44 22 0 n.s. 0.007 
SM 33 22 0 n.s. 0.028 
SGC 67 56 28 n.s. n.s. 
 
n.s. = not significant; AFB(+) = patient with pulmonary TB diagnosed by a positive AFB smear; 
non-TB = patients with pulmonary disease other than TB (pneumonia); HC: healthy controls; 
cell wall lipid abbreviations described in Methods section.  
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Figure 2.6: Lipid locations in the lipid-protein overlay assay (LPOA) 
strip:  Image shows the position of 15 different biologically active lipids prespotted 
on the hydrophobic strip membrane.  Every spot contained 100 pmol of the annotated 
cell membrane lipid.  The LOPA strips were stored at 2 to 8 °C and used once.  The 
LPOA strips have a diagonal cut on their top left corner and are spotted with 
Xylene Cyanol FF (blue) at the bottom right blank corner to assist with 
orientation of the strip.  Ponceau S staining (pink) was added to the lipid spots.   
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Figure 2.7: Lipid-protein overlay assay:  Image shows the results of autoradiography of IgM 
antibodies against cell wall lipids in TB and non-TB using the LPOA strip. Spotted lipids are 
shown in Figure 2.6. Panel A shows a non-TB patient; panel B shows a TB patient.  Circle spots 
represent chemilumiscence signals for the presence of IgM antibody after a 1 min exposure of the 
film.    
A                 B  
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CHAPTER 3 
 
Biological basis for anti-phospholipid IgM antibody production during TB infection 
and treatment in mice 
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I. Introduction 
 Anti-phospholipid IgM antibodies have a non-traditional B cell origin.  It is widely 
accepted that two types of B cells contribute to the production of antibodies against lipid 
antigens: B-1 and B-2 B cells. Both are able to make antibodies against lipids, however they each 
do this in a different way.  B-2 B cells require migration into the secondary lymph organ (SLO) 
and T helper cells for activation; whereas B-1 B cells are ready and able to secrete antibodies 
within the infection site (Hardy 2006; Montecino-Rodriguez and Dorshkind 2006).  B-1 cells can 
be subdivided further into two lineages known as B-1a and B-1b (Hardy 2006).  As discussed in 
Chapter 1, B-1 cells have very little or no memory and they are mainly located in pleural and 
peritoneal cavities, whereas B-2 cells primarily circulate in peripheral blood (Figure 1.1, 
Chapter 1).  B-1 cells express high levels of IgM antibodies and do not require T cell helpers, 
since they self-renew from pre-existing B-1 cells (Deenen and Kroese 1993).  Additionally, B-1 
cells have a shorter half-life than B-2 cells with B-1a cells having a 50% renewal time of 38 
days, while the B-2 cell renewal time is 45 days (Deenen and Kroese 1993).  B-1 cells also lack 
somatic hypermutation and thus have restricted diversity in the variable region of antibody heavy 
and light chains (Hardy 2006).  These characteristics suggest that natural antibodies produced by 
B-1 cells contribute to the innate immunity of the host (Baumgarth, Tung et al. 2005; Racine, 
Chatterjee et al. 2008). These natural antibodies are mainly of the IgM type and are polyreactive 
with an estimated half-life of about 8 hours (Sigounas, Kolaitis et al. 1994).  Despite this 
knowledge, the exact pathways of B-1 B cell activation and development during TB infection are 
not well understood and are still debated.   
 
 B-1 cells respond rapidly and strongly to host-derived innate signals, such as interleukin 
5 (IL-5), and to pathogen signals, which mainly consist of lipids, such as lipopolysacharides and 
phosphorylcholine (Takatsu, Kouro et al. 2009).  IL-5 is produced from the T cells that are 
recruited during TB infection and granuloma formation.  It is not clear if the lung alveolar 
epithelial cells also produce and sustain levels of IL-5. However, the high ratio of epithelial cells 
to lymphocytes in the lung supports the idea that epithelial cells are the primary IL-5 producing 
cells during infection. The secretion of IL-5 may be favorable for M. tuberculosis because it 
skews the host response towards Th2-type antibody mediated immunity, which is not known to 
have a protective role during TB infection.  Interestingly, in cells collected from the air spaces 
within the lungs of TB patients by a bronchoalveolar lavage (BAL) procedure, there was a higher 
frequency of purified protein derivative (PPD)-specific IL-5 secreting cells than in their 
peripheral blood monocyte cells (PBMC) (Morosini, Meloni et al. 2005). It is still unclear 
whether epithelial cells or lymphocytes in the BAL are the main cell repertoire responsible for 
the secretion of IL-5.  In addition, the levels of IL-5 expressed in situ gradually increased with 
the progression of TB compared to the levels of IL-5 from circulating cells. Thus, disease 
severity may influence the levels of IL-5 in the lung (Somoskovi, Zissel et al. 1999).  IL-5 is not 
detectable in pleural fluids surrounding the lungs of TB patients, possibly because pleural fluid 
cells and circulating blood take up this cytokine.  This evidence supports the conceptual model 
that during active disease, IL-5 is released in the lung and, together with lipids derived from M. 
tuberculosis, provides the signals required to stimulate and sustain the proliferation and survival 
of secreting B-1 cells and therefore, the innate B cell response at the site of infection (Barnes, Lu 
et al. 1993; Takatsu, Kouro et al. 2009).   
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B-1 B cells migrate to the lung of the infected TB host.  Recent evidence from Russo et 
al in 2010 showed that in mice infected with Mycobacterium bovis bacillus Calmette-Guerin 
(BCG), B-1 cells are present within the pulmonary lesions (Russo and Mariano 2010).  They also 
showed that B-1 B cells migrate from the peritoneal cavity to the infected lung, modulate the 
histological pattern of the inflammation, influence the influx of other cells to the infected lung, 
and favor resistance to the mycobacteria (Russo and Mariano 2010).  In addition, Barberio 
showed that B-1 B cells in vitro secrete IL-10 in response to lipopolysaccharide (LPS) (Barbeiro, 
Barbeiro et al. 2011).  In support of this evidence, studies by Chan et al have provided 
histological sections of lungs from infected mice that reveal the presence of B cells and their 
progressive increase in number during the course of TB infection in mice (Tsai, Chakravarty et 
al. 2006; Maglione, Xu et al. 2007; Maglione and Chan 2009).  We have yet to determine the 
specific role that B-1 B cells have in the formation of granuloma and lymphoid follicles within 
the lungs of the infected host. Nevertheless, when considered together, these observations imply 
that during active disease, the activation of B-1 B cells occurs inside the lung and depends on IL-
5 levels and pathogen associated molecular patterns (PAMPs), most likely lipopolysaccharide 
(LPS) and phospholipids.  Others have described the accumulation of tuberculin-like lipid 
molecules that occurs inside the cavity and caseous granulomas (Shima, Dannenberg et al. 1972; 
Converse, Dannenberg et al. 1996; Cosma, Humbert et al. 2004; Helke, Mankowski et al. 2006; 
Swaim, Connolly et al. 2006).  It is possible that phospholipids originate not only from 
replicating bacilli but from dead host cells within the granulomatous caseous lesions.   
B cells regulate the recruitment of macrophages to the M. tuberculosis infection site 
within the lung.  As discussed in Chapter 1, the granuloma formation by macrophages and 
lymphocytes is the hallmark immune response for infection control and containment within the 
lung.  A recent report showed that levels of IL-10 are higher in co-cultures of B cells with 
macrophages in vitro.  Chan et al has also demonstrated that the total B cell response within the 
lungs of  infected mice might inhibit cell mediated immunity and favor disease progression 
(Maglione, Xu et al. 2007; Maglione and Chan 2009).  Previous results from our laboratory using 
a novel adjunctive therapeutic vaccine to treat TB in mice, showed a significantly lower 
macrophage:lymphocyte ratio in vaccinated versus unvaccinated mice (Miyata 2011).  Thus, we 
hypothesize that TB healing or successful treatment will be reflected by a decrease in anti-
phospholipid IgM in the serum of treated mice.  
   We propose that the decrease in the bacterial burden in the lung during TB treatment will 
be reflected by a reduction in lipid antigens, and therefore a reduction in the responsive signals 
derived from the stimulation and development of B-1 cells.  The natural IgM antibody levels 
should decrease in proportion to the decrease in pathogen lipids as well as the degree of lesion 
healing upon successful treatment (Romanowski, Sutherland et al. 1991).  We anticipate a 
distinct antibody level change according to acute or chronic infection status in our mouse 
infection model.  
 
 In Chapter 2, we showed biological evidence supporting the hypothesis that antibody 
responses due to B-1 cells may be used as biomarkers of infection, since the level of antibody 
response to M. tuberculosis lipids may correlate with bacterial burden during active disease.  
Therefore, measurable changes in the level of antibody response could serve as a marker for 
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successful response to treatment.  To test this hypothesis, we studied changes in levels of anti-
phospholipid IgM antibody during TB infection and treatment in mice during acute and chronic 
infection.  We also investigated the levels of IL-5 and other pro- and anti-inflammatory 
cytokines in the infection site and in the secondary lymphoid organ."
II. Methods 
A. Cornell model of mouse infection: Eight-week-old female BALB/c mice (Jackson 
Laboratories) were maintained and studied at UC Berkeley’s Biosafety Level 3 
(BSL3) Northwest animal facility.  We infected the mice with M. tuberculosis H37Rv 
(American Type Culture Collection strain 25618) via aerosol route with the inhalation 
exposure system (IES, Glas-co, Terre Haute, Ind.) using a protocol previously 
adapted in our laboratory (Cheigh, Senaratne et al. 2010; Marjanovic, Miyata et al. 
2010). Two batches of 30 mice each were placed in the IES and exposed to a single 
M. tuberculosis bacilli solution for 60 min intervals. The right lung was obtained 
from mice grouped in the day 1 post-infection time-point to assess the initial bacterial 
inoculum.  Then, additional right lung samples were obtained at 4, 12, 20, and 28 
weeks post infection.  To assess the bacterial burden, we homogenized right lungs in 
PBS-Tween (0.05%), and plated the homogenate onto Mildebrook 7H11 agar plates 
containing oleic acid-albumin-dextrose-catalase supplement (OADC) (Becton 
Dickinson), 0.5% glycerol, and cyclohexamide (l00 ug/ml Sigma Aldrich).  Plates 
were read and colony forming units (CFU's) per lung were enumerated 21 days later.  
 
B. Antibiotic treatment in mice:  At 4 weeks after infection, mice were given isoniazid 
(100 "g/mL) and pyrazinamide (15 mg/mL) in drinking water ad libitum for 8 weeks.  
These mice were considered to be acutely infected (AI). Mice designated as 
chronically infected (CI) received the same treatment, but this was started at week 20 
post-infection (p.i.).  Mice were followed in order to evaluate clinical symptoms, lung 
CFU counts, and organ cytokine levels.  Healthy control (HC) mice were not infected 
and did not receive any treatment.  Three mice from each group were used for organ 
collection at each time-point.  
 
C. Determination of cytokines and anti-phospholipid IgM antibodies:  Whole blood, 
left lung and spleen were collected at the time of sacrifice.  Blood was allowed to 
coagulate for 30 min and was centrifuged at 13,000 rpm for 15 min.  Serum was 
separated and sterilized by filtration by a 0.2 µm disc filter (Difco, CA, USA) and 
stored at -80°C.  Left lung and spleen were homogenized in PBS-Tween (0.05%) and 
centrifuged at 13,000 rpm for 15 min.  The supernatant was filter sterilized as 
described above and then stored at -80°C.  Standard procedures for cleaning, 
disinfection and transport of samples to the BSL2 laboratory were followed.  For 
comparison and to assess specificity, we used a Salmonella mouse infection model to 
compare the anti-cardiolipin IgM levels.  Briefly, BALB/c mice were infected with 1 
x 10^E CFU of Salmonella per mouse intragastrically. Infected mice were 
anaesthetized and blood was collected via cardiac puncture at day 2, 5, 7, 14 and 28 
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p.i.  Collected blood was mixed with heparin to 50 units/ml and centrifuged at 8,000 
rpm for 5 minutes.  As healthy controls, we used 70-day old uninfected BALB/c 
mice. Serum was collected and stored at -70 C until use.   
 In the BSL2 laboratory, mouse serum from TB and Samonella infected mice was 
used to assay for anti-phospholipid IgM antibody by an in-house ELISA, which will 
be described in greater detail in Chapter 4.  IL-5, MCP-1, IL-10, TNF#, and IFN! 
concentrations from serum, lung, and spleen supernatants were determined with 
commercial kits from eBioscience (Cat No. 88-7054-22, 88-7054-22, 88-7104, 88-
7324-22, 7314, San Diego, CA, USA).  The limits of detection (LOD) for these kits 
were 4, 15, 30, 8 and 15 pg/ml for IL-5, MCP-1, IL-10, TNF#, and IFN!, 
respectively.  Samples were analyzed according to the manufacturer’s protocol.  
Standard curves were prepared following the manufacturer’s instructions and 
cytokine concentrations are given in pg/ml.   
 
D.   Statistical Analysis: The mean CFU counts of M. tuberculosis recovered from 
the organs of each mouse group as well the anti-phospholipid antibody levels and 
cytokine levels were compared with the Student's t-test.  Data are presented as line 
and bar graphs that indicate the mean and standard deviation for each group of 3 
mice.  All assays were performed in triplicate.  Differences between the mean CFU 
counts, antibody and cytokine levels obtained from each group were considered 
significant at p < 0.05. 
 
III. Results  
A. Bacterial load in CI and AI mice decreases with treatment: The M. tuberculosis-
exposed mice in our study followed two different timelines of infection and anti-TB 
treatment.  The initial inoculum enumeration at 24 hours p.i. for both sets of aerosol 
infected mice reached an average of 73 and 101 CFU per lung, respectively. 
Statistical analysis of these two inoculum levels revealed no differences (p= 0.6460, 
data not shown) between the two groups.  Thus, the average initial inoculum for our 
study sample was estimated at 87 CFUs. We randomized all of the infected mice into 
two groups across our study; AI and CI.  At week 4, both AI and CI groups reached a 
total average of 105 to 106 CFUs per lung.  This is consistent with the number of 
bacteria previously found by our laboratory using this model of mouse infection 
(Cheigh, Senaratne et al. 2010; Marjanovic, Miyata et al. 2010).   
 
  At week 12 p.i., after eight weeks of treatment with INH and PZA, the AI mice 
group showed no detectable M. tuberculosis bacilli by culture.  This group continued 
to have no detectable bacilli at weeks 20 and 28 p.i. In contrast, CI mice had 105 CFU 
per lung at week 20 p.i. The CFUs decreased to non-detectable levels after eight 
weeks of treatment at week 28 p.i. (Figure 3.1).  
 
B. IL-5 levels are higher in lung than serum and spleen: There were higher levels of 
IL-5 in the lung than in the spleen of CI and AI mice at week 20 p.i. The lungs of CI 
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and AI mice achieved average IL-5 levels of 1242 and 873 pg/ml, whereas the spleen 
of these mice reached an average of 136 and 328 pg/ml, respectively. No detectable 
levels of IL-5 were found in the serum of AI, CI or HC mice groups.  At week 12 p.i., 
there was no change in levels of IL-5 in the lungs of the AI and CI mice. At week 28 
p.i., the levels of IL-5 in CI mice after anti-TB treatment showed a decrease to levels 
similar to those of the HC and AI groups (Figure 3.2). 
 
C. IFN! and IL-10 are lower in spleen of AI mice after treatment: Spleen homogenate 
supernatant showed significantly lower levels of IFN! at week 12 p.i. (week eight of 
treatment) in AI mice compared to the CI mice which had not received treatment at 
that time (p=0.002).  The spleen IFN! levels in AI mice were similar to healthy 
controls.  In contrast, the spleen of the AI treated group did not show significantly 
lower levels of IL-10 than CI group.  These lower levels were also comparable to 
those of the healthy control mice.  TNF# was almost undetectable in AI and HC mice, 
whereas CI mice showed higher levels of this cytokine (Figure 3.3).  There were no 
significant differences in the levels of TNF#, IFN! and IL-10 in the lungs of AI and 
CI mouse groups at week 12 p.i. (Figure 3.4). 
 
 
D. Levels of anti-phospholipid IgM antibody in AI mice decrease after treatment.   
Levels of anti-cardiolipin IgM antibodies showed a significant decrease at week 12 
after the treatment of AI groups.  There were no significant differences in the levels 
of anti-phospholipid antibodies detected at day 1 and week 4 post-infection in the AI 
and CI groups.  AI mice showed anti-phospholipid IgM antibody levels similar to 
those of healthy mice at all time points.  The IgM antibody response against CL, PTC, 
PI and SL was significantly higher in CI mice at 12 weeks p.i. than in AI mice.  There 
was no significant difference in anti-PE IgM antibody levels (p=0.0635) between CI 
and AI mice after treatment (Figure 3.5a to 3.5e).  
 
  Anti-PTC IgM antibodies remained significantly higher in CI mice than in AI 
mice at 12, 20 and 28 weeks p.i. The anti-PTC IgM antibody levels in CI mice 
decreased to levels similar to those of AI and HC mice at 32 weeks p.i. (data not 
shown).  This indicates that the sensitivity of the IgM response to PTC is greater, 
since the anti-PTC levels changed to normal levels in response to successful anti-TB 
treatment in chronically infected mice.  The IgM levels correlated with the bacterial 
load in the mouse lung, with treated mice showing no M. tuberculosis CFU after eight 
weeks of treatment.   
a.  In the Salmonella mouse model of infection, the levels of anti-cardiolipin IgM 
at days 2, 5, 7, 14 and 21 days p.i. were lower than the levels of anti-
cardiolipin IgM antibody in AI and CI mice at week 4 p.i. in the Cornell 
mouse model   (Figure 3.7).  The Salmonella infected mice at day 28 p.i. 
show levels of anti-cardiolipin IgM antibody similar to those of AI and CI 
mice at week 4 p.i. The 10 week-old healthy control mice from the Salmonella 
mouse model (non-infected mice) showed lower levels of anti-cardiolipin IgM 
antibodies than the 12 week-old healthy control mice from the Cornell mouse 
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model (see Figure 3.5a and Figure 3.7) 
 
E. MCP-1 decreases in lungs of AI mice after treatment.  At week 12 p.i. lung levels of 
MCP-1 were significantly lower in AI mice after treatment when compared with CI 
mice (1028 vs 1567 pg/ml, p=0.011).  Spleen MCP-1 levels of AI, CI, and HC mice 
were significantly lower than the levels found in the lung. There were no detectable 
levels of MCP-1 in serum from all three groups (Figure 3.6).  
 
III. Discussion  
This study aimed to produce preliminary data and to provide initial insight into the 
biology of B-1 B cell activation and the production of anti-phospholipid IgM antibodies 
using the Cornell model of animal infection. These findings need to be complemented with 
further immunohistological studies looking at B-1 B cell surface markers to understand their 
distribution within the lung and their role in granuloma formation and resolution. Our 
laboratory is currently establishing and adapting protocols to accomplish this.  In addition, 
ex-vivo experiments using primary culture of B-1 B cells isolated from the lungs of TB 
infected mice will provide detailed information about cellular interactions in-vivo.   
 In this dissertation research, BALB/c mice were infected with M. tuberculosis by aerosol 
route and then treated with anti-tuberculosis drugs.  In contrast to the murine experiments 
presented in Chapter 2, we treated mice during acute infection (week 4 p.i.) and chronic 
infection (week 20 p.i.) stages to determine changes in anti-phospholipid IgM antibody 
response.  Additionally, we investigated the contribution of IL-5 to the activation of B-1 B 
cells and measured two pro-inflammatory cytokines, IFN! and TNF#, and one anti-
inflammatory cytokine, IL-10.  We also evaluated the role of MCP-1 as an associated 
biomarker cytokine related to macrophage activation during TB infection and inflammation 
processes. 
Our study showed that anti-phospholipid IgM antibody levels against CL significantly 
decreased at week 12 p.i. after eight weeks of treatment.  In contrast, the anti-PTC, PI, and 
SL IgM did not decrease, but showed significantly lower levels after eight weeks of 
treatment in acutely infected mice at the same time point.  These lower IgM levels 
corresponded to a reduction in the bacterial load. Levels of anti-PTC IgM remained 
significantly low in AI mice at up to 28 weeks p.i. In contrast, there were no significant 
difference in anti-PE IgM antibody levels between chronically infected mice and acutely 
infected mice after treatment.  When we compare these results with the Salmonella infection 
model, the levels of anti-cardiolipin IgM antibody were found to be similar to those in the 
acute infection in mice infected with M. tuberculosis.  The Salmonella infected mice died at 
one month p.i. and did not achieve higher IgM antibody levels similar to those of CI mice 
during M. tuberculosis infection.   These findings suggest that IgM response to infection does 
not occur in all types of infection, since Salmonella infected mice did not show elevated anti-
cardiolipin IgM at the time of death, when infection reached its maximum phase.   
We also found that IL-5 levels are higher in the lungs of CI mice versus HC mice 
before anti-TB treatment.  The spleen had significantly lower levels of IL-5 and serum had 
no detectable levels as measured by our in-house ELISA platform.  These results support the 
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hypothesis that most of the IL-5 dependent B-1 B cell activation takes place within the lung.  
Further investigation has been initiated in our laboratory to evaluate histological lung 
sections from infected mice, which will help to answer this question.  We plan to search for 
cell surface markers in lung collections of BALB/c and B6 mice infected with M. 
tuberculosis wild type, Erdman and BCG strains as well as other strains with lipid 
metabolism mutations, including mce1A-/-, mce1R-/- and fad5-/-. Observations by other 
researchers allow us to hypothesize that T lymphocytes recruited to the lung upon TB 
infection might contribute to IL-5 secretion and subsequent activation of B-1 B cells 
(Takatsu, Kouro et al. 2009).  While many groups have shown that the major cellular sources 
of IL-5 are Th2 cells, Tc2 cells, mast cells, eosinophils and !$T cells, there is also evidence 
that NK cells, NK T cells, or nonhematopoietic cells, including epithelial cells, have the 
ability to secrete IL-5 (Tominaga, Matsumoto et al. 1988; Desreumaux, Janin et al. 1992; 
Warren, Kinnear et al. 1995; Muramatsu, Sankaranand et al. 1999; Montecino-Rodriguez, 
Leathers et al. 2006; Sakuishi, Oki et al. 2007). However, our work has not yet determined 
which cell repertoires are responsible for the secretion of IL-5 in the lungs of the TB infected 
hosts.  
The location of B-1 B cells within M. tuberculosis infected lung is not clear. While 
others have demonstrated that B cells are located within the lung by detecting plasma cell 
surface markers in lung tissue, the exact location of B-1 B cells during TB infection has not 
been investigated.  Interestingly, polyclonal activation of B cells upon infection has recently 
been described in another mycobacterial infection-leprosy.  Studies of serum from leprosy 
patients have identified a wide spectrum of auto-antibodies including anti-cardiolipin (aCL), 
a rheumatoid factor and anti-phospholipid antibody (Saraux, Allain et al. 1996; de Larranaga, 
Forastiero et al. 2000).  We expect to gain a complete understanding from future projects of 
how B-1 B cells migrate into the lung during infection; as well as the series of changes that 
these cells undergo during anti-TB treatment.  
The evidence presented above supports our hypothesis that anti-phospholipid IgM 
antibodies might serve as a biomarker-based test to monitor anti-TB treatment.  Our results 
show an increased level of anti-phospholipid IgM antibodies during acute and chronic 
infection.  We also observed that healthy control mice have a continuous increase in these 
anti-phospholipid IgM antibodies with age.   These findings in healthy mice are consistent 
with previous observations by Montecino et al where B-1 B populations in the peritoneal 
cavity also increased with the age of mice (Hardy 2006; Montecino-Rodriguez and 
Dorshkind 2006).  Thus, it is expected that older healthy mice will have higher basal levels of 
anti-phopholipid IgM antibody.  Our study also showed this increase. We also demonstrated 
that higher levels of IL-5 are found in the lung versus the serum and spleen.  It is unclear if 
IgM antibody levels may contribute to host defense or immunopathology.  The correlation of 
IgM antibodies with the progressive infection in mice suggests that these antibodies play no 
role in protection.  In contrast, these antibodies are a direct reflection of the inflammation 
status of TB infection within the lung, and a decrease in these antibodies reflects a reduction 
of the bacterial burden in the lung.  Thus, measures of this anti-phospholipid IgM antibody in 
serum might be a suitable biomarker for monitoring treatment response.  Chapter 4 will 
provide the results of a validation study in humans we conducted to test this hypothesis.  
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IV. Figures 
 
 
 
 
 
 
  Figure 3.1: Bacterial burden in infected mice 
Colony forming unit enumeration per lung collected from infected mice at the specified time 
points. The green line represents acutely infected (AI) mice that recived treatment starting at 
week 4 p.i..  The red line represents chronically infected (CI) mice that received treament 
starting at week 20 p.i..  Green and red shaded areas indicate the eight week treatment 
periods of AI and CI groups respectively. Significant differnces between both groups are 
designated by an asterisk (p < 0.05).   
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Figure 3.2:  Levels of IL-5 during the treatment of CI mice group.  Levels of IL-5 are 
shown in pg/ml.   Each measure was obtained by assays using samples from three mice per 
assay.  Red bars correspond to chronic infection (CI) and blue bars to healthy control mice 
(HC). 
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Figure 3.3: Pro- and anti-inflammatory cytokine levels in the spleen of mice at week 12 
p.i.  Levels of TNF#, IFN! and IL-10 are shown in pg/ml. Significant differences are 
indicated with a p value and a black bar.  Each measure was obtained by assays using 
samples from three mice per assay.  Red bars correspond to chronic infection (CI), green 
bars correspond to acute infection (AI) and blue to healthy control mice (HC).  
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Figure 3.4: Pro- and anti-inflammatory cytokine levels in the lungs of infected mice at 
week 12 p.i.  Levels of TNF#, IFN! and IL-10 are shown in pg/ml. Each measure was 
obtained by assays using samples from three mice per assay.  Red bars correspond to 
chronic infection (CI), green bars correspond to acute infection (AI) and blue bars to healthy 
control mice (HC). 
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Fig 3.5a-3.5e: Levels of anti-phospholipid IgM antibodies in the Cornell model of mouse 
infections.  Levels of IgM antibodies in serum are shown in O.D.  Significant differences 
between the groups at a given timepoint are indicated by an asterisk in the X axis (p < 0.05). 
Each measure was obtained by assay of serum from three mice per assay.  Red lines correspond 
to chronic infection (CI), green lines correspond to acute infection (AI) and blue lines to healthy 
control mice (HC).  Green and red shaded areas indicate the eight week treatment periods of AI 
and CI groups respectively. 
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Figure 3.6: MCP-1 levels in serum, lung, and spleen after treatment of acute infected 
mice at week 12 p.i.  Levels of cytokines are shown in pg/ml. Significant differences are 
indicated with a p value and black bar. Each measure was obtained by assays using samples 
from three mice per assay.  Red bars correspond to chronic infection (CI), green bars 
correspond to acute infection (AI) and blue bars to healthy control mice (HC). 
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Figure 3.7: anti-cardiolipin IgM antibody levels during Salmonella model of mice 
infection.  Levels of IgM antibodies in serum are shown in O.D.  Groups of 2-5 mice were 
used to collect serum at each time point following oral infection by Salmonella.  For the 
uninfected mice (control), mice were sacrificed at approximately 70 days of age. 
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CHAPTER 4 
Validation of anti-phospholipid IgM antibodies as biomarker  
for monitoring TB treatment response 
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I.  Introduction 
The anti-lipid antibody response in mice is different than in human hosts.  Mice have 
an incomplete set of CD1 molecules whereas humans have all isoforms of CD1 including 
CD1a through CD1e; mice only have CD1d and CD1e (Lang and Glatman-Freedman 2006).   
Differences in CD1 molecules might contribute to a different pattern of anti-phospholipid 
IgM antibody response during TB infection and treatment.  In addition, our findings reported 
in Chapter 3 are limited by the mice strain used.  In general, BALB/c mice are more 
susceptible to TB infection and the cell mediated immune response is weaker.  In contrast, 
B6 mice have been shown to be more resistant to artificial models of TB infection.  In 
addition, BALB/c mice do not generate lung cavities and these animals do not cough 
(Yamamura, Maeda et al. 1986; Dannenberg 2009).   Another limitation with our animal 
model is that current bioethical regulations at UC Berkeley did not allow blood extraction 
from the same mouse at consecutives time-point.  This situation prevented us from evaluating 
the anti-phospholipid IgM antibody level changes within an individual animal host.  For 
these reasons the findings in Chapter 3 are not necessarily applicable in a human host.  Thus, 
a human validation study is required to determine the utility of a biomarker-based test using 
anti-phospholipid IgM antibody to evaluate TB treatment response.     
 The anti-lipid antibody response is highly variable in humans.  As mentioned in Chapter 
1, Steingart et al described the lack of sensitivity of lipid-antibody response for diagnosis 
tests (Steingart, Dendukuri et al. 2008).  Little is known about how much the anti-lipid 
antibody response changes in the same patient during TB infection and treatment.  It is 
widely accepted that anti-phospholipid IgM antibodies produced by B-1 B cells are self-
reactive and they have been associated with autoimmune diseases such as systemic lupus 
erythematosus and anti-phospholipid syndrome (Ravirajan, Harmer et al. 1995; Tebo, 
Jaskowski et al. 2008).  The self and poly-reactive properties of anti-phospholipid IgM 
antibodies facilitate their rapid clearance from the blood stream. IgM will bind to self-
phospholipid motifs in host cells and lipid transporter structures, such as oxidized low-
density lipoprotein (oxLDL) (Binder and Silverman 2005), and these self-binding properties 
increase their clearance rate compared to antibodies with a highly specific protein antigen 
target.  The rapid clearance rate may permit the observation of changes in anti-phospholipid 
IgM antibody levels during a course of treatment for diseases such as tuberculosis. 
We propose that the B-1 B cell-produced IgM antibody response may serve as a 
biomarker for monitoring TB treatment in humans.  That is, IgM antibody response against 
phospholipids may decrease as the bacterial load decreases with successful treatment.  Such a 
response could serve as a marker for effective treatment response and an end-point 
assessment in clinical trials of new anti-TB drug regimens.  
 
II. Methods 
XII. Patient specimens: Serum samples were obtained at baseline (before initiation of 
drug therapy) and at the end of the intensive phase of therapy from 40 HIV-negative 
patients with acid-fast bacilli (AFB) smear and culture-confirmed pulmonary 
tuberculosis (PTB).  These patients were enrolled in the Center for Disease Control and 
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Prevention–Tuberculosis Trials Consortium (CDC-TBTC) randomized clinical trial 
conducted in Kampala, Uganda.  The patient cohort was composed of two groups: 20 
culture-positive patients (slow responders) and 20 culture-negative patients (fast 
responders) defined by culture status at the end of 40 doses of anti-TB combination 
treatment, which corresponds to eight weeks of treatment (5 doses per week). Patients 
were further categorized according to disease severity based on the findings of pre-
treatment chest radiographs (limited, moderate, and extensive based on a validated 
grading scheme) and whether or not cavitary lesions were present (cavity and no cavity) 
(Falk A 1969).  Serum samples were screened for levels of IgM antibodies against five 
phospholipids extracted from bovine sources available commercially (Avanti Polar 
Lipids, Alabama, USA).   
 
XIII. Enzyme-linked immunosorbent assay (ELISA): The phospholipid antigens 
included cardiolipin (CL), phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
phosphatidylcholine (PTC), and sphingolipid (SL). Lipids were diluted to 10 mg/ml in 
ethanol and 50µl of the solutions were dried overnight in flat bottom well polystyrene 
ELISA plates (Fisher Scientific, USA). ELISA plates were blocked with 100µl of 3% 
low fatty acid bovine serum albumin (BSA) (USBiologicals, USA) and washed with 
phosphate buffered saline (PBS) pH 7.4.  Frozen serum samples were thawed twice and 
diluted 1:100 in 3% low fatty acid BSA. The diluted samples were added to the plate and 
incubated for one hour at room temperature (RT), followed by three washes with PBS. 
Then, 100µl of 1:5,000 goat-derived anti-human IgM was labeled with horseradish 
peroxidase (HRP) (Thermo Scientific, Ill), diluted in PBS pH 7.4, and incubated at RT 
for 1hr and washed again with PBS. Finally, 100 µl of tetramethylbenzidine substrate 
(TMB) (Thermo Scientific Pierce, Illinois, USA) was added and the reaction was 
stopped immediately with 50µl of sulfuric acid 1M.   
Reactions were read within ten minutes at 450nm in a spectrophotometer 
(Cambridge Technologies, Massachusetts).  The results were read out as the average of 
optical densities (O.D.) of triplicate assays. Standard curves for our in-house ELISA 
were prepared with polyclonal human IgM (Thermo Scientific Pierce, Illinois, USA), 
which yielded a correlation coefficient R2 of 0.99.  The concentration of IgM in serum 
samples (in µg/ml) was calculated based on this standard curve.  High, medium, and low 
IgM level control samples were included in each assay.  Assays with control sample 
results outside two standard deviations were discarded and repeated. 
 
XIV. Statistical analysis: All statistical analyses were conducted with STATA 
(Version 11, STATA Corp., Texas).  The two-sample Wilcoxon rank-sum test was used 
to compare lipid-specific IgM concentration differences between fast and slow 
responders (at baseline and at the end of intensive phase of treatment). We performed a 
step-wise procedure to test for the following variables suspected to be biologically 
relevant to IgM antibody response during treatment: age, gender, body mass index 
(BMI), bilateral abnormalities, AFB smear status at baseline, cavitary disease, and 
disease severity. Variables were added to the basic model in a stepwise fashion. 
Variables were eliminated from the full model if they failed to achieve significance at the 
 49 
5% level in order to obtain the best fit and simplest model.  The resulting model included 
cavity classification and disease severity as significant variables. The Wilcoxon signed-
rank nonparametric test was used to compare lipid-specific antibody differences between 
groups for cavity and disease severity variables.  The Committee for Protection of 
Human Subjects at UC Berkeley (UCB#2010-06-1752) approved this sub-study.  The 
protocol for the parent clinical trial (conducted by the TB Trials Consortium sponsored 
by the U.S. Centers for Disease Control and Prevention; ClinicalTrials.gov number, 
NCT00694629) was approved by the Center for Disease Control and Prevention IRB and 
the local IRBs at all participating sites. All patients gave informed consent for 
participation.  
 
III. Results: 
The CDC-TBTC sample set was composed of 40 HIV-negative patients (29 males and 
11 females) with smear and culture-confirmed pulmonary TB.  The baseline characteristics of 
the study subjects are shown in Table 1. The average age was 29 years (range 19 to 53 years of 
age).  Seventy-seven percent of these patients were non-smokers, one patient had a past history 
of excessive alcohol use, and one patient had used non-injectable drugs within the last year.  
(Table 4.1). Patients with negative culture after 2 months of treatment showed a higher 
pretreatment BMI.  This is similar to previous findings where BMI was the strongest predictor 
of culture status (Visser, Grewal et al. 2011).  Three patients had limited radiographic disease, 
21 had moderate disease, and 16 had extensive disease. Fifty-eight percent had cavitary lesions. 
The anti-phospholipid IgM antibody response was highly variable among these patients. 
A global analysis of our sample set showed heterogeneous results for all five anti-phospholipid 
IgM levels, regardless of culture conversion status (data not shown).  A comparison of the 
change in IgM antibody levels between TB patients who remained culture positive and those 
who culture converted after 40 doses of intense therapy, revealed no significant differences using 
a two-sample t- test (data not shown).   
The multi-variable model included age, gender, body mass index, bilateral abnormalities, 
smear status at baseline, cavity extension and disease extension.  This model revealed no 
contribution of the variables to changes in antibody levels upon treatment completion.  Thus, we 
opted to use a simpler model using “cavity classification” as a proxy for disease severity and 
adjusted for “age”.  The “cavity classification” variable showed a uniform distribution across 
three categories, including no cavity (n= 17), small cavity (n= 9), and large cavity (n= 14). This 
simpler model allowed us to study the anti-phospholipid IgM antibodies as a biomarker for TB 
treatment response, despite the variability of the antibody levels within our sample set.  
Analysis of this simpler model consistently showed a decrease in IgM anti-phospholipids 
antibodies among TB patients with no lung cavities.  The mean IgM concentration decreased 
significantly in four of the five phospholipids, including PE, PI, PTC and SL (paired t-student p= 
0.008, 0.016, 0.020, and 0.043 respectively).  The distribution of delta change among all patients 
was scattered due to the presence of outliers in the cavity classification categories (data not 
shown). The median values of antibody change were analyzed with a two-sample Wilcoxon 
rank-sum test that found a significant decrease for all five lipids, CL, PI, PE, PTC, and SL in 
non-cavitary TB patients (Wilcoxon rank-sum test p= 0.036, 0.006, 0.001, 0.007, 0.040 
respectively, see Figure 4.1).  The antibody level reduction was different for each lipid as we 
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observed a 22.7%, 11.1%, 15.4%, 24.3% and 18.0% concentration reduction of IgM anti-CL, PE, 
PI, PTC and SL, respectively (data not shown).   
In contrast, patients with cavitary TB showed an overall increase in the anti-phospholipid 
IgM antibody response following anti-TB drug treatment.  A significant increase was observed in 
anti-PE antibody levels (p= 0.025, 95% C.I.-2.287, -0.113).  
We evaluated our biomarker test’s ability to identify successful treatment response in 
non-cavitary TB patients.  We defined a positive biomarker test as a decrease in anti-
phospholipid IgM antibodies and a negative test as an increase or no change in anti-phospholipid 
IgM antibodies.  The outcome was successful treatment response.  The sensitivity values were 
88.2%, 70.6%, 76.5%, 88.2% and 76.5% for each anti-CL, PE, PI, PTC and SL IgM, 
respectively, with an overall sensitivity of 80% (Table 4.2).  The sensitivity was 94% in non-
cavitary disease patients when the decrease in IgM response was assessed against 2 or more of 
the phospholipids (CL and PTC, or CL, PTC, and PI).   
 
IV. Discussion 
Changes in serum anti-phospholipid IgM antibodies appear to be a useful biomarker test 
to monitor treatment response in TB patients, especially in patients with non-cavitary disease.  
The decrease in patients without cavitary disease may be related to the decrease in bacterial 
burden and healing of lung lesions in these patients. In contrast, patients with cavitary disease 
showed a significant increase in antibody levels after 40 doses of treatment.  This increase may 
reflect liquefied caseum containing high levels of M. tuberculosis bacilli and their lipid debris, as 
well as host cells’ phospholipids released during the inflammatory process (Converse, 
Dannenberg et al. 1996; Dannenberg 2009).  This increase might be transient during treatment, 
but additional studies assessing antibody levels at later time points are needed to support this 
suggestion.     
The pathophysiology of cavity formation and healing during TB is not completely 
understood (Gadkowski and Stout 2008).  Evidence from human cavities suggests that Th2 
cytokines, such as IL-4 and TNF#, may play a role in cavity formation (Somoskovi, Zissel et al. 
1999).  These Th2 cytokines may antagonize host defenses and cause tissue necrosis in TB 
patients’ lungs (van Crevel, Karyadi et al. 2000).  Early work by Yamamura et al. showed that a 
lipid-protein mixture from heat-killed bacilli sensitized and elicited cavities in white male rabbits 
(Yamamura, Maeda et al. 1986).  Interestingly, this study demonstrated that mycobacterial 
proteins alone were able to produce granulomas, but not cavities.  More recently, it has been 
shown that mycobacterial lipids act as adjuvants as mycobacterial proteins combined with 
synthetic adjuvants were able to elicit cavity formation (Helke, Mankowski et al. 2006).  Once 
the cavity breaks open and communication with the bronchial tree is established, more oxygen 
enters allowing the bacilli to multiply further inside the cavity (Palaci, Dietze et al. 2007).  
Routine cultures have measured 107- 109 bacilli within the liquefied material of a single cavity.  
 We hypothesize that IgM secreting B-1 B cells are activated upon treatment by the 
transiently enhanced inflammation induced by dying M. tuberculosis in cavitary lesions.  
Necrotic cells accumulate lipids in the caseum and this may explain the increase in the anti-lipid 
IgM antibody levels we observed in treated patients with cavitary disease in this study.  Both 
lipids from dead host cells and from M. tuberculosis in the released caseous material contain 
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sufficient levels of antigens to activate the B-1 B cells and induce anti-phospholipid IgM 
antibody production.  It has also been observed that TB patients have higher levels of PPD-
specific IL-5 secreting cells in their bronchoalveolar lavage (BAL) than peripheral blood 
mononuclear cells (PBMC) (Morosini, Meloni et al. 2005).  More recently, it was shown that 
increased levels of neutrophils and granulocytes occur during TB pathogenesis in guinea pigs 
and humans (Ordway, Palanisamy et al. 2007; Eum, Kong et al. 2010; Russo and Mariano 2010).  
These studies indicate that CD4+ lymphocytes are initially the predominant inflammatory cells 
within the lungs.  After 30 days, increased B cells and granulocytes have been associated with 
worsening lung pathology.  Furthermore, lungs of BCG infected BALB/c mice have shown a 
significant increase in B-1 B cells at 40 days post infection (Russo and Mariano 2010). Thus, 
self-lipids, mycobacterial lipids, and IL-5 secreted by granulocytes generate the signaling 
required for full activation of B-1 B cells. The increase in anti-phospholipid IgM antibodies 
observed in cavitary TB patients might be a reflection of T cell-independent B-1 B cell activation 
upon cavity liquefaction during TB treatment.  
 The percentage of TB patients with cavitary disease at initial diagnosis varies by 
geographical region.  Countries with low and mid TB incidence such as Saudi Arabia, Denmark, 
and Brazil report cavities on the initial chest X-ray in 14%, 42%, and 36% of TB patients, 
respectively (Nyman, Brismar et al. 1996; Wilcke, Askgaard et al. 1998; Gomes, Saad Junior et 
al. 2003).  In contrast, Nigeria, a country with a high prevalence of TB, has reported the presence 
of cavities in up to 46% of cases (Andreu, Caceres et al. 2004).  Our biomarker anti-phospholipid 
IgM antibody test will be useful to monitor the treatment of 64-86% of the patients suffering 
from TB, depending on the cavitary TB prevalence in the region.  
 The change in anti-phospholipid IgM antibody levels may also serve as a valuable test to 
monitor TB treatment in HIV-positive patients.  As mentioned previously, B-1 B cells do not 
require T cells for activation.  Therefore CD4+ and CD8+ cell counts will not affect the anti-
phospholipid IgM antibody levels produced in patients infected with HIV.  In addition, HIV-
positive patients generally do not develop cavitary TB because of a weakened cell-mediated 
immune response.  The anti-phospholipid IgM antibodies in TB-HIV infected patients could be 
useful in monitoring disease severity.   
The proportions of non-cavitary TB patients that showed a decrease in IgM response 
were 88.2%, 70.6%, 76.5%, 88.2% and 76.5% for IgM anti-CL, PE, PI, PTC and SL, 
respectively (Table 2).  Since all of the patients responded to the treatment, these values also 
represent the sensitivity of our IgM biomarker ELISA test.  At eight weeks of treatment, these 
values were all higher than the reported 60-80% sensitivity of the 2-month sputum culture 
conversion method currently in use to monitor treatment response (Liu, Shilkret et al. 1999; 
Salihu, Aliyu et al. 2003; Alguire and Medicine 2008; Uzundag Iseri, Dulkar et al. 2010).  Since 
a large proportion of sputum cultures from newly diagnosed patients are negative before 
treatment, the sensitivity of the traditional monitoring test is actually even lower.  The anti-
phospholipid IgM ELISA does not require sputum culture results. 
 This study is limited by the fact that it included patients who all responded to the drug 
regimens given.  Our test still needs to be studied with a larger sample size that also includes 
patients who do not respond to treatment.  If our biomarker-based test can be shown to also have 
high specificity for those that respond to treatment, it can serve as a low-cost method to monitor 
response to treatment.  The bovine phospholipids used in this study were all readily 
commercially available and can be used in low concentrations. In most countries, chest x-rays 
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are routinely performed as part of TB diagnostic work ups.  Thus, the combination of chest x-ray 
and anti-lipid IgM response results could serve an inexpensive and sensitive approach to monitor 
response to TB treatment.  
 
V. Future directions  
 The findings of this dissertation research open a new set of questions.   The discovery of M. 
tuberculosis cardiolipin as lipid biomarker, together with the anti-phospholipid IgM antibody 
response in animal models and its the validation in the human host anti-TB therapy does not 
answer all the questions.  It still remains unclear whether or not this biomarker-based test is 
useful in HIV co-infected patients. Additionally, it is necessary to determine if this biomarker-
based test is useful for monitoring the treatment of other infectious diseases of the lung, like 
pneumonia.  We must also determine if our biomarker test’s performance will differ between fast 
and slow responders, both with initial non-cavitary TB.    In addition, we believe it is necessary 
to understand the biology behind the increase in anti-phospholipid antibodies during cavitary TB.   
Our current mouse model of infection does not produce cavitary TB, but rabbits and guinea pigs 
hosts can be used in order to address this issue.  It is essential to determine the exact location of 
B-1 B cell activation within the infected lung.  Immunohistochemistry using surface cell markers 
for IgM, CD5 and CD11b will be a key in this research.  Finally, the clearance dynamics of B-1 
B cells during lung healing upon anti-TB treatment needs to be clarified.    In summary, the 
results reported here represent one small portion of a huge area of basic and applied research.   
Our laboratory has recently started analyzing surface markers to study the cell repertoire within 
the lung of infected mice.   We expect to soon generate new information to facilitate the study of 
these remaining unanswered questions.   
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VI.  Tables and figures 
 
Table 4.1. Demographic and clinical characteristics of TB patients who responded early 
(sputum culture negative at 8 weeks of treatment) and late (sputum culture positive at 8 
weeks). 
 Culture negative at 8 weeks (n = 20) 
Culture positive 
at 8 weeks  (n = 20) 
Demographic characteristics   
Age; median (IQR) 25.0 (6.0) 30.0 (4.0) 
Male gender 13 (65%) 16 (85%) 
Social characteristics   
Smoking history 4 (20%) 5 (25%) 
Excessive alcohol use in the past 0 (0%) 1 (5%) 
Past drug use last year (injection) 0 (0%) 0 (0%) 
Past drug use last year (non-injection) 0 (0%) 1 (5%) 
Clinical characteristics   
BMI; median (IQR) 19.8 (2.8) 18.6 (2.5) 
HIV infected 0 (0%) 0 (0%) 
Any co-morbid condition 1 (5%) 0 (0%) 
TB diagnosis   
Any cavity at baseline chest radiograph 12 (60%) 11 (55%) 
Bilateral cavitation 1 (5%) 2 (10%) 
Cavity classification   
Cavity absent 8 (40%) 9 (45%) 
Cavity present with < 4cm diameter 5 (25%) 4 (20%) 
Cavity present with % 4cm diameter 7 (35%) 7 (35%) 
Extent of Chest x-ray involvement   
Limited 0 (0%) 3 (15%) 
Moderate 14 (70%) 7 (35%) 
Extensive 6 (30%) 10 (50%) 
Any bilateral abnormalities 8 (40%) 12 (60%) 
AFB smear   
2+ 4 (20%) 0 (0%) 
3+ 6 (30%) 7 (35%) 
4+ 10 (50%) 13 (65%) 
Days to detection; median (IQR) 5.84 (2.54) 5.83 (2.38) 
TB treatment   
Received pretreatment 4 (20%) 1 (5%) 
Days of pretreatment 0 (0%) 0 (0%) 
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Table 4.2: Biomarker test evaluation for monitoring treatment response in non-cavitary 
TBa. 
 
 Non-Cavitary TB decreased 
Sensitivity 
% 
CL 15/17 88.2  
PE 12/17 70.6  
PI 13/17 76.5  
PTC 15/17 88.2  
SL 13/17 76.5  
 
 
aNumber of non-cavitary TB patients that showed a decrease in anti-phospholipid IgM antibody 
levels. Values for sensitivity were determined for each lipid using contingency table analysis.   
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Figure 4.1: Plots of the median change of IgM anti-phospholipids antibody levels after 40 
doses of intensive phase anti-TB drug therapy.  Antibody levels were determined by in-house 
ELISA assay; and results are shown in concentration ("g/ml). The panels compare the antibody 
decrease in cavitary TB patients vs non-cavitary TB patients for each of the five phospholipids 
including Cardiolipin (CL); phosphatidyl ethanolamine (PE); Phosphatidyl Inositol (PI); 
Phosphatidyl Choline (PTC); Sphingolipid (SL).  Asterisks indicate a significant increase or 
decrease (p<0.05) in the corresponding anti-phospholipid IgM antibody.  
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CHAPTER 5 
 
CONCLUSIONS 
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 Tuberculosis (TB) is a major threat to public health worldwide. The global effort for TB 
control urgently requires a major shift to improve the tests that are currently used for TB 
diagnosis and prognosis of treatment outcome.  Until now, pathogen-signal based tests have been 
implemented without a dramatic effect in reducing the TB burden.  The pathogen signal-based 
tests are more expensive and technologically complicated.  In contrast, biomarker-based tests are 
cheaper and simpler alternatives for rapid implementation in low resources settings where TB is 
highly prevalent.  This dissertation thesis proposes to measure anti-phospholipid IgM antibodies 
as a biomarker-based test for monitoring TB treatment response. 
 
Chapter 1 discussed TB as a major threat to public health worldwide and described the 
current challenges in diagnosis and treatment as well the rationale and need for new biomarker-
based tests.  This chapter also illustrated the wide repertoire of lipids located within M. 
tuberculosis cell walls that can be used as potential targets of novel lipid-antibody-based 
biomarkers.  Specifically, antibodies generated by B-1 B cells have the characteristics of an 
innate immunity response and therefore might reflect infection status in a host.  This chapter also 
discussed the biological understanding which allowed us to hypothesize that anti-lipid IgM 
antibodies secreted by B-1 B cells might reflect the burden of M. tuberculosis bacilli inside the 
lungs and that these antibodies decrease with anti-tuberculosis treatment.  A similar antibody 
monitoring approach has been demonstrated to monitor the treatment of syphilis.  This 
dissertation thesis proposes that in patients with pulmonary TB, the levels of anti-lipid IgM 
antibodies might also decrease with treatment.   
 
The lipid screening and discovery approach described in Chapter 2 resulted in the 
identification of M. tuberculosis cardiolipin (CL) as the major lipid antigen during active disease.  
The TLC-I technique developed in our laboratory guided us in screening most of the lipid 
antigens found in M. tuberculosis cell wall.  We identified a band in the TLC-I containing a lipid 
antigen to which 100% of TB patients showed an IgM antibody response.  Wet chemistry 
including flash chromatography, two dimensional TLC and mass spectrometry allowed us to 
identify cardiolipin in this band fraction. This finding allowed us to hypothesize that CL,  as well 
as other phospholipids, might be useful antigens for a lipid-antibody biomarker-based method to 
monitor the treatment response.  
 
Chapter 3 attempted to understand the biology of anti-phospholipid IgM antibody 
production and decrease during TB infection and treatment of mice.  Our findings indicate that 
indeed, anti-phospholipid IgM levels against different phospholipids, including CL, PTC, PI, and 
SL, decreased significantly after eight weeks of treatment in acute infected mice (AI).  Levels of 
anti-PTC IgM antibodies remained significantly low in AI mice up to 28 weeks p.i. We found no 
significant difference in anti-PE IgM antibody levels between AI mice and CI mice. 
Interestingly, higher levels of IL-5 were found in the lungs of infected mice.  This finding raises 
new questions about which cells within the lung secrete IL-5 during TB infection and how this 
relates to B-1 B cell activation. We also observed that the levels of the chemokine MCP-1 
secreted by macrophages decrease after treatment of acute infected mice. Taking these findings 
together, we hypothesize that anti-phospholipid IgM antibodies produced by B-1 B cells may be 
a useful biomarker to monitor treatment response in infected mice. 
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Finally, Chapter 4 presented the results of a study testing the use of anti-phospholipid 
IgM antibody as a biomarker for monitoring the treatment response in human hosts with 
pulmonary TB.  Here we studied IgM antibodies during the first intensive phase of anti-TB drug 
therapy using an in-house ELISA platform.  Our findings showed that patients with non-cavitary 
TB significantly decrease in anti-CL, -PTC, -PI, -PE and -SL IgM antibodies during the first 8 
weeks of treatment.  In contrast, during cavitary TB there is an increase, with a significant 
increase only in anti-PE IgM antibodies. No significant differences in IgM levels for any lipids 
were found between fast and slow responders.  The sensitivity of this biomarker-based test in 
non-cavitary TB patients ranged from 71% to 88%.  We anticipate that additional research is 
needed to understand the significance of using this as a biomarker of cavitation or severity of 
disease. 
 
All these observations together allowed us to propose the use of anti-phospholipid IgM 
antibodies as the basis for a biomarker-based test to monitor TB treatment response.  Currently 
other members in our laboratory are continuing with the development of a point-of-care (POC) 
test for use in limited resource settings.  There are three platforms under evaluation, including 
lateral flow assay (LFA), mini-ELISA (mELISA), and silica embedded polyacrylamide (SEP). 
Prototype devices will be tested in collaborator sites in Brazil and Panama as we plan to 
collaborate with TB control programs in high burden cities within these countries.  In addition, 
our laboratory has started to investigate the cellular dynamics within the lung of infected mice 
during treatment and vaccination.  This approach will initially include the characterization of cell 
repertoires of histological sections of mice lung using surface cell markers and con-focal 
florescent microscopy. We anticipate that both investigations will provide new insights that will 
facilitate a better understanding of the use and biology of the anti-phospholipid antibodies.  We 
strongly believe that this new information, together with the biomarker-based test proposed here, 
will have a large positive impact on the management of patients with pulmonary TB and the 
efforts to control the disease worldwide.  
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